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CHAPTER 1 
INTRODUCTION 
Diabetes 
Diabetes Mellitus is a chronic condition in which the pancreatic beta cells are rendered 
incapable of generating adequate insulin to meet the metabolic demands or when the tissues 
are unable to efficiently utilize the synthesized insulin due to increasing insulin resistance [1]. 
The overall outcome of either of these conditions is a systemic increase in the levels of glucose 
circulating in the bloodstream, leading to hyperglycemia. Diabetes is associated with major 
complications such as, nephropathy, retinopathy, neuropathy, cardiac diseases and even 
premature death. According to the International Diabetes Federation [IDF] the worldwide 
incidence of diabetes in 2012 was 371 million and has since then risen unabatedly to 387 million 
in 2014 [with 46% undiagnosed cases]. The reports predict a drastic escalation of this number 
to 592 million by 2035. Growing along with the diabetes prevalence is the healthcare 
expenditure on diabetes, which was $612 billion for the year 2014 alone. Table 1-1 and Figure 
1-1 depict the prevalence of diabetes in various geographical regions across the globe along 
with the respective percentage of undiagnosed cases. 
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Table 1-1: International Diabetes Federation estimates of worldwide prevalence of Diabetes 
[2014]. [http://www.idf.org/diabetesatlas] 
 
 
International Diabetes Federation 2014 estimates of worldwide prevalence of 
Diabetes 
REGION PEOPLE LIVING 
WITH 
DIABETES 
PERCENT 
PREVALENCE
UNDIAGNOSED 
CASES 
North America and 
Caribbean (NAC) 
39 Million 11.4% 27.1% 
South and Central 
America (SACA) 
25 Million 8.1% 27.4% 
Europe (EUR) 52 Million 7.9% 33.1% 
Middle East and North 
Africa (MENA) 
37 Million 9.7% 48.6% 
Africa (AFR) 22 Million 5.1% 62.5% 
South-East Asia (SEA) 75 Million 8.3% 52.8% 
Western Pacific (WP) 138 Million 8.5% 53.6% 
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Figure 1-1: Worldwide incidence of Diabetes and projected increase of the disease by 2035 
International Diabetes Federation estimates 2014. [http://www.idf.org/diabetesatlas] 
Type 1 Diabetes Mellitus [T1DM] and Type 2 Diabetes Mellitus [T2DM] are the 2 major forms of 
diabetes. 
T1DM: Previously called as juvenile onset diabetes, T1DM occurs early on in the 
developmental stages during childhood or adolescence, and is a result of autoimmune-mediated 
death of the beta cells of the islets of Langerhans. This results in a severe deficiency in the 
synthesis and secretion of insulin by the pancreas. Genetic predisposition as well as 
environmental factors could trigger the immune system to cause beta cell death in this form of 
the disease. Patients with T1DM require daily doses of insulin for glucose homeostasis. 
T2DM:  T2DM is now a global health crisis and approximately 90% of cases of diabetes 
fall under this class making it the most common form of diabetes. It is characterized by insulin 
resistance manifested by target tissues [adipose, muscle], which the beta cells initially try to 
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compensate for by synthesizing additional amounts of insulin [hyperinsulinemia]. However, as 
the disease progresses, the beta cells are unable to cope with the rapidly rising blood glucose 
levels and in due course, a decline in the secretion of insulin by the islet beta cells is observed, 
followed by absolute insulin deficiency, hyperglycemia and onset of diabetes. 
Pancreatic islets 
The islets of Langerhans derive their name from the German pathologist Dr. Paul 
Langerhans, who discovered this hormone-producing cluster of cells in the year 1869. The islets 
are found in the pancreas, located in the abdominal cavity posterior to the stomach. Typically a 
normal adult pancreas contains approximately a million islets. Each islet shows a well organized 
structure made up of 3 main types of cells: alpha [15-20%], beta [~65–80%] and delta [~3-10%] 
cells which secrete glucagon, insulin and somatostatin, respectively. Besides these, the islets 
also contain small number of pancreatic polypeptide [PP] cells which produce pancreatic 
polypeptide and Epsilon cells that secrete ghrelin [2, 3]. 
Figure 1-2: Pancreatic islets obtained from normal male, 8 week old, Sprague Dawley rats 
observed under light microscope. [The above image is a representative preparation that were 
used in my studies]  
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Fundamental role of beta cells in insulin secretion and maintenance of glucose 
homeostasis  
Under physiological conditions, a balance between the levels of glucose circulating in the 
blood and the amount of glucose that the cells need for energy is tightly regulated, thus maintaining 
glucose homeostasis. A balanced production and secretion of hormones by the islet cells is 
essential towards maintaining optimum levels of glucose in the blood. After a meal, as the level 
of glucose in blood circulation ascends, the beta cells respond by secreting insulin. This 
facilitates the uptake of glucose by the muscle and adipose cells, thereby bringing the blood glucose 
levels back to a normal level. On the other hand, when blood glucose levels are low, the alpha cells 
release glucagon. This hormone exerts its stimulatory action on the liver, inducing the release of 
stored glucose from glycogen, and in doing so; glucose homeostasis is re-established [4]. 
The process of insulin secretion is very tightly regulated and involves a few key steps.  
1. An increase in the blood glucose levels causes the uptake of glucose molecules by 
the GLUT-2 transporters located on the beta cells. 
2. The internalized glucose undergoes metabolism generating high amounts of ATP 
in the process.  
3. As the ATP/ADP ratio in the cell increases, it causes the closing of the ATP 
sensitive K+ channels, resulting in membrane depolarization.  
4. Following this, the voltage dependent Ca++ channels open up leading to influx of 
Ca++ ions into the cell. 
5. Ca++ promotes the movement of insulin-laden secretory granules towards the 
plasma membrane where they fuse and release the insulin [5]. 
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Factors that impair insulin release into the bloodstream cause a reduction in glucose uptake by the 
insulin-sensitive muscle and adipose tissues, which leads to increased levels of glucose circulating 
in the blood or hyperglycemia, a hallmark of T2DM.   
Pathogenesis of T2DM 
Beta cell dysfunction and insulin resistance are the 2 major contributing factors to the 
pathogenesis of T2DM. However, a lot remains to be understood in regard to the exact 
mechanisms that the beta cells undergo during these events. Insulin secretion by the beta cell 
occurs in a biphasic fashion; with the first phase burst occurring within 5-10 minutes of glucose 
ingestion, with the release of insulin from the granules docked at the membrane, followed by a 
steady second phase, which involves the mobilization of the insulin granules from the reserve 
pool in the cell towards the plasma membrane for exocytosis [6]. Insulin release is considered 
as a direct measure of beta cell function and any impairment in either phase of insulin secretion, 
chiefly the first phase, may be the earliest evidence of an individual’s progression towards 
T2DM.  Assessment of insulin secretion as a function for beta cell performance is most 
commonly done by measurement of fasting plasma insulin concentrations, HOMA-B index 
[fasting insulin to fasting glucose ratios], plasma C-peptide concentrations, acute insulin 
response [7, 8]. Insulin resistance is manifested by impairment in uptake of glucose by the 
insulin sensitive tissues [muscle and adipose] and could be a result of genetic and 
environmental factors, diet-induced obesity, inflammatory cytokines or cellular stress signaling.  
There has been considerable deliberation over the specific contribution of beta cell failure and 
insulin resistance and sequence of occurrence of either of these events towards the progression 
of T2DM.  However, the two events are not mutually exclusive and there exists a feedback 
communication between them [7]. The beta cell tries to play a compensatory role under 
conditions of insulin resistance, and as T2DM progresses the exhausted beta cell is unable to 
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cope with the increasing metabolic demands, culminating in beta cell dysfunction/damage. 
Therefore, most of the therapeutic modalities for T2DM involve treatments to improve insulin 
resistance and/or beta cell survival and function. 
 
Figure 1-3: Pathogenesis of T2DM. [http://t2ddb.ibab.ac.in/t2ddb_desc.shtml]  
Genetic Factors Environmental Factors
Poor diet, sedentary lifestyle, obesityPrimary beta‐cell defects
Impaired insulin secretion Peripheral tissue insulin resistance
Inadequate glucose utilization
Hyperglycemia
Beta‐cell dysfunction/damage
Type‐2 diabetes
Insulin deficiency
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Animal models of T2DM 
Generally, animal models of T2DM display obesity and manifest insulin resistance 
and/or beta cell dysfunction. Table 1-2 enlists the most common animal models used in T2DM 
research along with the method of induction and basic features [9, 10 and 11]. 
Model T2DM induction method Features 
Lep ob/ob mice 
[Obese] 
 
Spontaneous mutation in ob 
gene coding for the protein leptin 
Leptin deficiency 
Exhibit rapid weight gain ~2 
weeks 
Obesity induced hyperglycemia 
Develop hyperinsulinemia and 
insulin resistance in 3-4 weeks 
Lepr db/db mice 
[Obese] 
 
Autosomal recessive mutation in 
Leptin receptor gene- Lepr  
Leptin receptor deficient 
Hyperinsulinemia and insulin 
resistant [~2 weeks] 
Obesity [~3-4 weeks]  
Hyperglycemia [~4-8 weeks] due 
to beta cell failure 
Short life span 
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Zucker Diabetic 
Fatty [ZDF] rat 
[Obese] 
 
Point mutation in Leptin receptor 
gene- Lepr  
Obesity  [~4 weeks]induced 
hyperglycemia [~7 weeks] 
Hyperinsulinemia followed by 
decrease in insulin levels 
Diabetes develops at  ~8-10 
weeks 
Kuo Kondo [KK] 
mice  
Mildly obese  polygenic model of 
T2DM and obesity 
Obesity induced hyperglycemia 
Severe hyperinsulinemia and 
insulin resistance in muscle and 
adipose tissue 
High fat feeding 
[C57BL/6] mice 
Diet/Nutrition induced obesity Obesity induced hyperglycemia 
Hyperinsulinemia 
Weight gain linked to insulin 
resistance 
Glucose intolerance due to beta 
cell insufficiency 
Goto-Kakizaki [GK] 
rat 
Non-obese Defective glucose induced insulin 
secretion 
10 
 
 
 
Hyperglycemia caused by loss of 
beta cell function   
Akita mice 
[Ins2Akita]  
Mutation in insulin gene-
Ins2,causing misfolding of insulin 
in the ER resulting in beta cell 
damage/death  
Pancreatic beta cell damage due 
to ER stress 
Table 1-2: Key features of most common animal models of T2DM 
Nuclear lamins 
 The nucleus of a cell is surrounded by a protective bilayer; comprised of the inner 
nuclear membrane [INM] and the outer nuclear membrane [ONM], which are collectively called 
the nuclear envelope [NE]. The globular form of the nucleus is held together by a network of 
filaments on the inner surface of the INM that provide mechanical support and maintain nuclear 
integrity [12]. This network of filaments is known as the nuclear lamina and the major proteins of 
the lamina are the nuclear lamins which are type V intermediate filaments [IF]. The lamin protein 
network in the nucleus is situated on the inner [nucleoplasm facing] side of the INM, in close 
proximity to the outer fringes of chromatin [13]. In addition to being important elements of the 
nuclear architecture, the nuclear lamins play an essential role in critical functions of the nucleus, 
such as nucleoplasmic organization of chromatin, DNA replication and damage repair [14, 15, 
and 16].  
 The lamin protein family is classified on the basis of the gene responsible for encoding of 
that particular lamin. Therefore, in humans, lamin A and C which are formed by alternative 
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splicing of the gene LMNA are placed in the same class [Type A] along with scarce isoforms, 
A∆10 and C2, whereas lamin B1 and B2/B3, which are encoded by the genes LMNB1 and 
LMNB2 respectively, are Type B lamins. Type A lamins are expressed in differentiated cells, 
have neutral isoelectric points whereas, at least one of the type B lamins is expressed in every 
cell irrespective of differentiation status, have acidic isoelectric points, and during mitosis tend to 
remain associated with the nuclear membrane [17-19].  
 Depicted in Figure 1-4 is the biochemical structure of the lamins proteins. All lamins 
have the typical structure of IF proteins, with a central α-helical “rod domain” having a non-α-
helical N-terminal ‘‘head’’ and C-terminal ‘‘tail’ [called as immunoglobulin, Ig-like β-fold domain] 
on either ends. A nuclear localization sequence [NLS] segment, which facilitates nuclear 
targeting of lamins, consists of a lysine residue, followed by three other basic residues [K or R]; 
and lies in between the central rod domain and Ig-like β fold. Furthermore, all lamins except 
mammalian and drosophila lamin C [Figure 1-4] possess a C-terminal Ras-like CAAX-box motif 
composed of a cysteine [C], two aliphatic amino acid residues [AA], and any amino acid residue 
[X], and are subjected to a complex series of post-translational modifications, including 
prenylation [incorporation of C15 or C20 carbon metabolites derived from the cholesterol 
biosynthesis pathway], proteolytic cleaving and carboxylmethylation [20].  
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Figure 1-4: Protein structure of lamins. [Modified from Burke et al., Ref. 21] 
 
Functions of nuclear lamina in cellular physiology and nuclear processes: 
1) Mechanical Support:  
 A number of early studies have described lamins as structures comparable to IFs which 
are insoluble in non ionic detergents [22-24]. Further studies involving mutational analyses of 
nuclear lamina proteins [lamins A, C and B1] by Lammerding and associates demonstrated a 
decrease in nuclear rigidity in cells devoid of lamins A and C exhibiting frailty of the nucleus, 
A C
B
B1 B2
LMNA gene 
(alternative splicing  )
LMNB1 
gene
LMNB2 
gene
586/620Central Rod Domain NLS IG like -foldHead Domain
Lamin B1/B2 CAAX
CAAX
664Central Rod Domain NLS IG like -foldHead Domain
Pre-lamin A
646
Lamin A
572
Lamin C
LAMINS
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which leads to increased cell death induced by mechanical stress. Lamin B1-deficient cells 
however, did not display aberrant nuclear mechanics, even though appearance of nuclear blebs 
increased significantly [25]. Another rheological study conducted on lamin B 1 filaments 
demonstrates that these filaments exhibit tough elasticity when exposed to shear stress and the 
disintegration of the nuclear envelope would entail mechanical stress as well as biochemical 
alterations of lamin B1 [26]. These studies highlight the importance of lamins A and C in 
maintaining the mechanical stiffness of nuclei, and lamin B1 towards preserving nuclear 
integrity. 
2) Chromatin Organization: 
 At the molecular level, lamins bind to regions of the chromatin via chromatin binding 
proteins or by direct interaction. It has been shown that lamins form attachments with histones, 
DNA and chromatin-associated protein apart from directly associating with Lamin B receptors 
[LBR]. An earlier study conducted by Taniura and colleagues has identified chromatin binding 
sites on the tail region of lamins C, B1 and B2 [27]. The transcriptionally silent heterochromatin 
is localized near the periphery of nuclei of most cells and lamins mediate the attachment of 
chromatin to the nuclear envelope. Studies conducted in LMNA knockout mice have shown that 
localization of the heterochromatin is completely lost from the nuclear periphery especially in 
fibroblasts and myocytes [28, 29]. Similar phenotypical abnormalities have been noted in 
fibroblasts of patients with Hutchinson–Gilford progeria syndrome [HGPS] — a clinical disorder 
caused by mutations in the LMNA gene [30].  
14 
 
 
3) DNA replication: 
 An increasing body of evidence suggests that lamins play a key role in regulating the 
complex DNA replication process. One such study by Moir et al. demonstrated, in 3T3 cells 
exposed to BrDU and stained with proliferating cell nuclear antigen [PCNA], that lamin B1 
localizes at the replication foci with BrDU and the replication factor PCNA in replication sites 
during “S phase”, suggesting the potential role of lamins in replication [31]. Most of the evidence 
showing the association of lamin and replication process is based on studies carried out in vitro 
in Xenopus egg interphase nuclei extracts. Xenopus eggs when immunodepleted with XLB3, a 
major lamin in this species, or when transfected with a dominant-negative N-terminally deleted 
mutant of lamin B1, exhibited a reduction in DNA replication [32-34]. Evidence for the 
importance of lamins in transcription is shown in studies with N-terminally deleted lamins, which 
disrupts the head-to-tail assembly of lamin dimers and the subsequent formation of lamin 
filament structures. This N-terminally deleted mutant of lamins, when inserted in Xenopus 
embryos, bring about dissociation of the lamina which then leads to a decrease in RNA 
polymerase II activity, which is directly involved in the process of transcription [35].  
Processing of pre-lamins for the formation of mature lamin filaments 
Post-Translational Modification  
 Post translational modifications [PTMs] are a series of steps implicated in the priming and 
processing of proteins and play a vital role in enhancing the functional range of the protein. 
They involve covalent addition of certain functional groups [phosphorylation, methylation, 
prenylation etc.], enzymatic cleavage of regulatory subunits or degradation of entire proteins 
[ubiquitination] and influence major facets of cell physiology and pathology. Identifying and 
understanding PTMs is critical in the study of cell biology and disease preclusion and therapy.  
15 
 
 
 
 
Figure 1-5: PTM steps involved in processing of nuclear lamins. [Modified from Burke et al., Ref. 
21] 
 Small molecular weight G-proteins, the ϒ subunits of trimeric G-proteins and nuclear 
lamins which possess the unique C-terminal amino acid sequences “CAAX motif” are ideal 
candidates for PTMs and serve as targets for isoprenylation and carboxymethylation. 
Isoprenylation is the enzyme-mediated addition of either 15 carbon farnesyl group or 20 carbon 
geranylgeranyl group at the C-terminal cysteine of the protein [36, 37].  
1
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 Lamins A, B1 and B2, which are initially translated in the form of pre-lamins, possess the 
C-terminal CAAX motif which marks the proteins for farnesylation of the cysteine residue [21]. 
Lamins require additional PTMs at CAAX box in order to be converted to their mature form. 
Soon after their synthesis, lamins are subjected to a multistep PTM process, in the following 
order: initial farnesylation by the enzyme farnesyltransferase [FTase], endoproteolytic cleavage 
of C-terminal -AAX amino acids by Ras converting enzyme 1 [Rce-1] or Zinc metallopeptidase 
[ZMPSTE24] and finally carboxymethylation by isoprenylcysteine carboxyl methyltransferase 
[ICMT] [38, 39]. B type lamins are permanently farnesylated and carboxymethylated while 
prelamin A undergoes an additional step of removal of 15 amino acids at the C-terminal by 
ZMPSTE24 to generate mature lamin A which lacks the modifications at the C-terminal. This 
step is unique to lamin A. Lamin C on the other hand, does not possess the CAAX motif and 
hence is not farnesylated or modified [21, 39, and 40].  
 Farnesylation:  
  The major purpose of these lipid post-translational modifications of lamins is directing 
them towards the membrane for protein-membrane interactions or protein-protein interactions 
for nuclear envelope assembly, which begins with the insertion of a 15 carbon farnesyl group at 
the C-terminal cysteine and is an irreversible modification [36]. Farnesyl pyrophosphate is a 
metabolite derived during the synthesis of cholesterol from mevalonate. The presence of CAAX 
motif at C-terminal of lamins marks them as target proteins for FTase-catalyzed farnesylation. 
FTase incorporates this 15 carbon derivative of mevalonate into the C-terminal cysteine residue 
which has been shown to increase the hydrophobicity of the proteins and results in membrane 
targeting [20]. A recent study by Jung and colleagues has highlighted the role of farnesylation of 
lamin B in neuronal development. They have developed knock-in mice expressing non-
farnesylated versions of lamin B1 and lamin B2. In this study, the non-farnesylated lamin B1 
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expressing mice died due to neuronal abnormalities since the chromatin could not be retained 
within the nuclear lamina during the process of neuronal migration [41]. 
 Endoproteolytic cleavage: 
 Endoproteolytic cleavage involves the shortening of the C-terminal by severing the last 3 
amino acids of the CAAX motif by either Rce-1 or ZMPSTE24, and the subsequent removal of 
the last 15 amino acids by ZMPSTE24 in the case of prelamin A producing mature lamin A [42]. 
Rce-1 is a type II CAAX prenyl endopeptidase with a wide specificity, processing all 
farnesylated and geranylgeranylated CAAX proteins while ZMPSTE24 is a type I CAAX 
processing enzyme and has a specific role in processing of prelamin A [43, 44]. These are 
integral membrane proteins that reside in the ER and INM. Recently, Manolaridis and 
associates have reported the crystal structure of an Rce-1 homologue from Methanococcus 
maripaludis, which has specificity for farnesylated peptides similar to that shown by eukaryotic 
Rce-1 [38].  
 Carboxymethylation: 
 The next step in the PTM of lamins is the addition of carboxymethyl group to farnesyl 
cysteine of CAAX box by ICMT, a prenyl-protein specific methyltransferase of the ER. Initial 
studies from our laboratory have characterized the carboxylmethylation of lamin by vapor phase 
equilibration assay using either [3H] S-adenosyl methionine in cell lysates or [3H]-methionine in 
intact cells. The initial observation characterized a protein in the molecular range of 65-70 kDa 
was carboxymethylated. Further, studies were carried out by immunoprecipitating the lysates or 
intact beta cells after incubating with [3H] S-adenosyl methionine or [3H]-methionine using anti-
lamin B antibody suggested that the methylated protein was lamin B [45].  
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 Although farnesylation of lamins is involved in increasing their hydrophobicity and driving 
them towards the nuclear membrane, both endoproteolytic cleavage and carboxymethylation 
play an essential role in the proper formation of the nuclear lamina as shown in a recent study 
by Maske et al. They have demonstrated that absence of endoproteolysis or carboxymethylation 
in the C-terminal of lamins would lead to distorted nuclear lamina [46]. 
 B type lamins are permanently farnesylated and carboxymethylated while prelamin A 
undergoes an additional endoproteolytic cleavage step and finally converts into mature lamin A 
[21]. Recently we have also shown in INS-1 832/13 cells that ICMT produces an increase in 
activity of a small molecular weight GTP binding protein, Rac1, which is essential for the 
assembly of NOX2. NOX2 holoenzyme assembly mediates the production of reactive oxygen 
species [ROS], which is necessary for GSIS [47].  
Nuclear lamina assembly and disassembly  
 Nuclear lamina assembly is a dynamic process that begins after the sister chromatids are 
formed during anaphase and in final stages of mitosis, especially telophase. The nuclear 
envelope [NE] and its associated structures start to reassemble around the separated sister 
chromosomes to form functional daughter nuclei. Nuclear reassembly is characterized at 
molecular level based on a tightly regulated sequence of protein interactions, which occur in the 
following order: [i] targeting of individual nucleoskeletal proteins to the chromosomal surface, [ii] 
membrane recruitment and fusion, [iii] assembly of nuclear pore complexes [NPCs], [iv] 
transport of the bulk of lamins into the nucleus through newly formed NPCs, and [v] formation of 
the nuclear lamina and, at the early G1 phase, the chromatin becomes fully enclosed by an 
intact NE. As the nucleus enlarges by import of nuclear proteins through NPCs, the NE expands 
and the chromatin becomes fully de-condensed. Being intermediate filament proteins, lamins 
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assemble together to form the nuclear lamina meshwork that remains connected during 
interphase, but disassembles during mitosis [48, 49]. 
 
Figure 1-6: Assembly and disassembly of the nuclear lamina. [Modified from Davidson et al. 
Ref. 50 and THE CELL, Third Edition Ref. 51]. 
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 Lamins [both A and B type] can self assemble into parallel coiled homodimers  and 
further associate to form head-to-tail molecular strings that are formed by electrostatic 
interactions between the overlapping ends of successive coiled-coil domains.  In the initial stage 
of lamina organization, two individual lamin monomers associate by winding around each other 
to form parallel coiled-coil structures. The structure of the central α-helical rod domain facilitates 
this dimer formation with the C-termini projecting out as globular heads. In conditions that favor 
lamina assembly, the dimers connect to form polymers by forming longitudinal head-to-tail links. 
These polymers subsequently form filaments by lateral association and finally emerge as 
paracrystals [52, 53].  
 Nuclear lamina disassembly occurs during mitosis as well as during apoptosis with 
several biochemical similarities in lamin filament dissociation occurring during both these 
processes [54, 55]. A key feature of apoptosis is reduction in nuclear size and chromatin 
condensation followed by chromatin fragmentation; during this process lamin proteins are 
cleaved by the cysteine-dependent aspartate-directed proteases, namely; caspases [56]; and 
this has been proposed as the main mechanism for lamina disassembly. For this to happen, 
prior phosphorylation by lamin kinases [e.g., protein kinases] is essential for the relaxation of 
lamin proteins for the access of caspases, followed by lamin disassembly. Activation of lamin 
kinases [protein kinase C-δ and protein Kinase C-βII] requires prior cleavage of the 
holoenzyme, to release C-terminal catalytic domain, by caspases [57, 58]. Recently, Cross et 
al. demonstrated that protein kinase C-δ gets activated by caspase 3, and translocates to the 
nuclear compartment and colocalizes with lamin B during apoptosis and inhibition of PKC-δ 
delayed caspase 3-mediated proteolysis of lamin B [59].  Furthermore, Eitel and associates 
have reported that kinase-negative PKC-δ mutant decreased free fatty acid-induced lamin B 
disassembly and cell death in pancreatic beta cells [60]. The nuclear lamins were one of the 
first proteins identified as caspase targets. The aspartic acid 230 of lamin A located [61] in the 
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2B region of the central rod domain, a highly conserved region in all known IF proteins is critical 
for polymerization and is recognized as caspase cleavage site. Each caspase has a distinct 
type of lamin as a substrate, which possesses a unique recognition sequence for the protease, 
despite the fact that the aspartic acid 230 residue is the target site for caspase cleavage in 
human lamins A and B1. Rao and colleagues have demonstrated that HeLa cells which are 
transfected with caspase-uncleavable mutants of lamins, displayed an impediment in the 
advancement of shrinkage process of the nucleus, and a slowdown in chromatin condensation 
and cell death [62].  
Diseases due to genetic mutations and improper processing of lamins 
  Most of the disease related mutations in lamins originate in the LMNA gene [e.g., 
Emery-Dreifuss muscular dystrophy, dilated cardiomyopathy, Hutchinson-Gilford Progeria 
Syndrome etc.] along with few others [Adult onset autosomal dominant leukodystrophy and 
Pelger-Huet anomaly], occurring due to mutations in the lamin B1 [LMNB1] gene and lamin B 
receptor [LBR] gene [63]. Enlisted in the table below are some of the major disorders 
associated with lamin protein family [also called ‘laminopathies’], the mutated genes and the 
phenotypical characteristics of the diseases [64-79]. 
Disease Lamin involved Mutation gene Clinical Phenotype 
Emery-Dreifuss 
Muscular 
Dystrophy 
Lamin A/C LMNA  Affects mainly skeletal and 
cardiac muscles 
 Phenotypical signs appear by 
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age 10 
 Joint deformities [contractures] 
at elbows and Achille’s tendon 
 Rigidity in spine and neck 
 Increasing muscle weakness 
and wasting 
 Most patients have cardiac 
complications by adulthood  
Restrictive 
Dermopathy 
Accumulation of 
farnesylated 
prelamin A 
ZMPSTE24  Lethal congenital skin condition 
 Intrauterine growth retardation 
 Tightening/rigidity of skin 
[especially of face and around 
the mouth] 
 Respiratory insufficiency 
 Most infants do not live long due 
to pulmonary problems 
Hutchinson-
Gilford Progeria 
Lamin A 
[accumulation of 
LMNA  Physical appearance is normal 
at birth 
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Syndrome. 
 
aberrant form of 
prelamin A 
‘progerin’] 
 Premature and accelerated 
aging 
 Reduction/absence of 
subcutaneous fat 
 Alopecia 
 Hearing loss 
 Most do not live beyond 13-14 
yrs 
 Death usually occurs due to 
cardiovascular diseases 
Dunnigan-type 
familial partial 
lipodystrophy 
[FPLD]  
Lamin A/C LMNA  Phenotypical appearance of the 
disease occurs during 
adolescence  
 Progressive loss of fat from 
limbs and trunk 
 Glucose intolerance 
 Hyperinsulinemia 
 Insulin resistance 
24 
 
 
 
  T2DM 
Adult Onset 
autosomal 
dominant 
leukodystrophy 
Lamin B1 
[Increased 
expression] 
LMNB1  Phenotype is similar to chronic 
progressive multiple sclerosis 
 Progressive neurological 
disorder 
 Autonomic dysfunction, e.g., low 
blood pressure, incontinence, 
blurred vision 
Charcot-Marie 
tooth disease, 
axonal Type 2B1 
Lamin A/C LMNA  Symptoms begin in late 
childhood/early adulthood  
 Progressive loss of muscle 
tissue and sensation 
 Mild sensory loss 
 Wasting and weakness of lower 
limbs 
Pelger-Huet 
anomaly 
Lamin B receptor LBR  Benign blood disorder 
[hyposegmentation of nucleus of 
WBCs/neutrophils] 
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 Mild skeletal malformation 
Dilated 
Cardiomyopathy 
Lamin A/C LMNA  Affects mainly cardiac muscle, 
skeletal muscle is minimally 
affected 
 Progressive ventricular dilation 
 Impaired systolic function 
 Pulmonary edema 
 
Table 1-3: Clinical features of laminopathies.  
Nuclear Lamins in beta cell and T2DM 
Beta cell damage is characterized by specific changes in the morphology of the cell. The 
cell undergoes shrinkage, blebbing [bulges in the plasma membrane], nuclear fragmentation 
and chromatin condensation. Degradation of lamins leads to the breakdown of nuclear lamina 
which is a preliminary stage of apoptosis as this is followed by DNA degradation and chromatin 
condensation [80].  It is well established that beta cell dysfunction and failure are characteristic 
features of Type 1 and 2 diabetes. Therefore, it is necessary to study the intracellular events 
that the pancreatic beta cell undergoes, and understanding of such events will aid in searching 
for a possible drug target for the management and/or prevention of the disease. So far, not 
much is known regarding the role of lamins in the etiology of diabetes, apart from some 
genome-wide association studies [GWAS]. GWAS typically focus on associations between 
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single-nucleotide polymorphisms [SNPs] and major diseases by comparing the genetic 
materials from normal and diseased state individuals. LMNA gene mutations are responsible for 
multiple clinically relevant disorders, such as Dunnigan-type familial partial lipodystrophy 
[FPLD]. Individuals with this disease display a characteristic loss of subcutaneous fat, insulin 
resistance, glucose intolerance, hypertension in addition to other phenotypical changes 
observed in metabolic syndrome. Hegele and associates were the first research group to 
discover that a cause of Dunnigan-type lipodystrophy, a body fat disorder which leads to 
diabetes, is mutation in LMNA gene in the chromosome 1q21.22 [81]. 
Role of caspases in nuclear lamin degradation  
The caspase family is one of the most important factors in the apoptotic pathway. Many 
proteins in the cell, including a large number of structural proteins, are cleaved by activated 
caspases which culminates in apoptosis of the cell. The caspase 8, 9 and 10 are initiator 
caspases whereas caspase 3, 6 and 7 are effector caspases. The initiator caspases cleave and 
activate the effector caspases leading to cell death [82]. These caspases exist in the form of 
inactive zymogens [also referred to as pro-caspases], which are activated by the process of 
cleavage by other upstream proteases or by auto- or trans-activation [83]. In the recent years a 
variety of substrates of caspases have been recognized [e.g., PARP, PKC-δ, nuclear lamins]. 
Caspase-dependent degradation of nuclear lamins has been identified as a precursor to nuclear 
lamina disassembly [56].  
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Glucotoxicity and the beta cell 
Figure 1-7: Acute and chronic effects of various glucose concentrations on the beta cell. 
[Modified from Bensallem et al. 2012, Ref. 84] 
A constant glucose overload on the beta cell causes reduced expression of Glut2, 
preproinsulin, Pdx-1, diminished glucose sensitivity and impairment in its basic function of 
insulin secretion and eventually beta cell damage [84, 85]. Figure 1-8 shows the effect of 
glucotoxicity on beta cell function and survival. Several intracellular signaling events have been 
identified as causal to high glucose-induced metabolic dysregulation of the islet. The most 
commonly studied are endoplasmic reticulum [ER] and oxidative stress. It has been suggested 
that both oxidative and ER stress lead to mitochondrial dysfunction, cytochrome C release, and 
caspase activation [86]. Recently, a multifunctional sorting protein, PACS-2 [phosphor-acidic 
cluster sorting protein 2], which controls the ER-mitochondria axis has been identified [87]. 
Despite this growing body of evidence, very little is known in the context of the islet beta cells on 
potential detrimental effects of glucotoxic conditions on ER, mitochondria, caspase activation 
and associated degradation of their respective substrate proteins. 
2 5 10 30 (mM Glucose)
Acute effects
Sub‐acute effects
Chronic effects
(Time)
‐↑Insulin secreƟon
‐↑Protein synthesis (proinsulin)
‐↑Ca2+ pumping into the ER
‐↑FuncƟon
‐↑ProliferaƟon and   
Differentiation
‐↑Survival
‐↓FuncƟon
‐↓ProliferaƟon and   
Differentiation
‐↑Apoptosis
Glucotoxicity
28 
 
 
 
On the basis of the above literature review, the central objective of my thesis work is to 
study the mechanisms involved in beta cell dysfunction in diabetes and to elucidate the role of 
ER-mitochondrial axis in initiating the activation of executioner caspases which leads to nuclear 
lamina disassembly in insulin-secreting INS-1 832/13 cells exposed to acute and/or long-term 
incubation conditions. In addition, I propose to extend these in vitro studies to islets obtained 
from animal models of obesity and T2DM [e.g., Zucker Diabetic Fatty - ZDF rat]. 
Based on this objective, I proposed to test the hypotheses that: [i] Exposure of 
pancreatic beta cells to glucotoxic conditions induces ER stress which causes caspase-
mediated lamin A & B degradation culminating in beta cell dysfunction; [ii] cross-talk between 
ER and mitochondria cause mitochondrial dysfunction leading to caspase activation and lamin 
degradation; and [iii] ER stress inhibitors and calcium channel blockers protect the pancreatic 
beta cell from glucotoxicity. A simplified working model based on these hypotheses has been 
depicted in Figure 1-8. 
I worked towards testing these hypotheses by conducting experiments under the following three 
Specific Aims: 
Specific Aim 1: To study the effect of glucotoxicity induced ER stress on pancreatic beta cells. 
Specific Aim 2: To establish a role of ER-mitochondrial communication in beta cell 
dysfunction/death and to determine the effects ER stress inhibitors and calcium channel 
blockers on pancreatic beta cells. 
Specific Aim 3: To investigate potential abnormalities involved in ER stress and mitochondrial 
dysfunction in animal models of impaired insulin secretion, obesity and diabetes. 
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 Specific Aim 4: To study the consequences of inhibition of requisite post translational 
prenylation of lamins on the pancreatic beta cell. 
 
Figure 1-8: Proposed working model for ER-stress induced, caspase-mediated degradation of 
nuclear lamins under glucotoxic conditions in pancreatic beta cells. We propose that exposure 
of insulin-secreting cells to high glucose leads to increased ER stress leading to mitochondrial 
dysfunction [86, 87]. As a consequence, cytosolic caspase 3 and 6 are activated by the 
released cytochrome C from the dysregulated mitochondria. Activation of caspases leads to 
degradation of lamin A and B culminating in nuclear damage and altered distribution of 
degraded lamins into various subcellular compartments, leading to nuclear lamina disassembly. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Materials 
Chemicals: Glucose, nifedipine, thapsigargin, 4-phenylbutyric acid, simvastatin, triton X-
114 were obtained from Sigma Aldrich [St. Louis, MO]. Inhibitors of caspase 3 [Z-DEVD-FMK] 
and caspase 6 [Z-VEID-FMK] were from Enzo Lifesciences [Farmingdale, NY]. FTI-277 was 
purchased from Tocris Biosciences [Minneapolis, MN]. GGTI-2147 was obtained from 
Calbiochem-EMD Millipore [Billerica, MA] and Rottlerin was procured from Cayman Chemical 
Company [Ann Arbor, MI].  
Antibodies: Antisera directed against lamin A, caspase 3, cleaved caspase 3, cleaved 
caspase 6, CHOP, phospho-p44/42 ERK1/2 [Thr202/Tyr204] and total p44/42 ERK1/2 were 
obtained from Cell Signaling [Danvers, MA]. Antibody for lamin B, phospho-p38MAPK and total-
p38MAPK was from Santa Cruz Biotechnology [Santa Cruz, CA]. Antibody for ZMPSTE24 was 
procured from Abcam [Cambridge, MA]. Anti-β actin was purchased from Sigma Aldrich [St. 
Louis, MO]. Anti-mouse IgG and Anti-rabbit IgG conjugated to horseradish peroxidase were 
from GE Healthcare [UK]. Anti-goat IgG conjugated to horseradish peroxidase was obtained 
from Santa Cruz Biotechnology [Santa Cruz, CA]. 
Assay kits: ELISA kit [Rat insulin] was procured from American Laboratory Products Co 
[Windham, NH]. Metabolic cell viability assay kit [MTT] was purchased from Sigma Aldrich [St. 
Louis, MO]. ProteoExtract - Subcellular Proteome Extraction Kit was obtained from EMD 
Millipore [Billerica, MA]. 
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Animals: Male Sprague-Dawley rats were purchased from Harlan Laboratories [Oxford, 
MI]. Male Zucker Diabetic fatty [ZDF] and Zucker Lean Control [ZLC] rats were obtained from 
Charles River Laboratories [Wilmington, MA]. All animals were maintained in a 12 hrs light/dark 
cycle with free access to water and food. The ZDF and ZLC rats were fed the Purina Diet 5008. 
Blood glucose was measured by tail vein puncture using Freestyle lite glucometer [Abott 
Diabetes Care, Inc., Alameda, CA]. 
2.2 INS-1 832/13 cells, rat islets and human islets: Culture conditions 
 INS-1 832/13 cells: INS-1 832/13 cells were kindly made available by Dr. Chris 
Newgard, Duke University Medical Center, Durham, NC. The cells were cultured and 
maintained in RPMI-1640 medium prepared with 10% heat inactivated Fetal Bovine Serum 
[FBS]. The medium was supplemented with antibiotics [100 IU/ml penicillin and streptomycin], 
10 mM HEPES, 1mM sodium pyruvate and 50 μM 2-mercaptoethanol [pH 7.4]. Passages 53-61 
were used for the studies. Cells were exposed to low and high glucose [2.5 and 20 mM] or 
simvastatin/FTI-277/GGTI-2147 for time periods ranging from 0-48 hrs as indicated in each 
study. For the studies involving pharmacological inhibitors, cells were pre-incubated with the 
compounds for either 1 or 12 hrs as indicated for each study, and then further treated with low 
and high glucose in the continuous presence or absence of inhibitors. At the end of the 
incubation period, the cells were harvested and lysed in radio immunoprecipitation assay [RIPA] 
buffer containing protease inhibitor cocktail, 1 mM NaF, 1 mM PMSF and 1 mM Na3VO4.  
Isolation of islets: All animal protocols were utilized after prior assessment and 
obtaining consent of the Institutional Animal Care and Use Committee at Wayne State 
University. Islets from normal 6-8 week-old male Sprague–Dawley rats were isolated by the 
collagenase digestion method, wherein collagenase was injected into the common bile duct of 
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the euthanized animal. The pancreata were then excised and digested at 37°C followed by 
density gradient purification using Histopaque 1077, in order to separate out islets from 
pancreatic acinar tissue. After isolation, islets were cultured overnight in RPMI-1640 medium 
containing 10% heat-inactivated FBS supplemented with 100 IU/ ml penicillin and 100 IU/ml 
streptomycin, 1 mM sodium pyruvate and 10 mM HEPES [pH 7.4] and further incubated in the 
low [2.5 mM] and high glucose [20 mM].  At the end of the incubation islets were harvested and 
lysed in RIPA buffer.  
Human islets: Human islets [~90-95% purity] from two normal [38-year-old female and 
64-year-old male] and one diabetic [44-year-old male] donors and islet culture medium were 
procured from Prodo Laboratories, Inc. [Irvine, CA].  Following incubations in the presence of 
low [5.8 mM] or high [30 mM] glucose, normal human islets and T2D human islets were 
homogenized in RIPA buffer and used for Western blotting. 
2.3 Isolation of subcellular fractions 
 Extraction of cytosolic, membrane/organelle and nucleic protein fraction was carried out as 
per the manufacturer’s instructions using the ProteoExtract® Subcellular Proteome Extraction Kit. 
INS-1 832/13 cells were exposed to low and high glucose for 24 hrs. The cells were scraped and 
suspended in wash buffer and pelleted by centrifugation for 10 min at 200 g at 4°C. The pellet 
obtained was then resuspended in the extraction buffer-I and protease inhibitor cocktail provided in 
the kit. After incubation for 10 min at 4°C the cells were centrifuged for 10 min at 750 g, the 
supernatant obtained was the cytosolic fraction. The pellet was then resuspended in Extraction 
buffer-II and protease inhibitor cocktail and incubated for 30 min and then centrifuged for 10 min at 
5500 g. The supernatant thus obtained was the membrane/organelle fraction. Finally the pellet was 
resuspended in extraction buffer-III, protease inhibitor cocktail and benzonase, incubated for 10 min 
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at 4°C and centrifuged at 6800 g for 10 min. The supernatant obtained was the nucleic protein 
fraction.  
2.4 Subcellular phase partitioning using Triton X-114 
 INS-1 832/13 cells were incubated overnight in low glucose and 2.5% FBS and FTI-277 
[10 µM]. Cells were then treated with media containing low glucose [2.5 mM] in the absence and 
presence of FTI-277 [10 µM] for 24 hrs. Cell lysates were homogenized in a homogenization 
buffer [20 mM Tris-HCl, pH 7.5, 0.5 mM EGTA, 2 mM MgCl2 and protease inhibitor cocktail] and 
subjected to a single-step centrifugation at 100,000g for 60 min at 4°C in order to separate the 
cytosol [supernatant] and the membrane [pellet] fractions. The membrane fraction was then 
subjected to phase partitioning using Triton X-114, a non-ionic detergent. Triton X-114 exists as 
a homogenous solution at 0°C; however, as the temperature rises upto 20°C, it splits into 
aqueous and detergent phases. This property is taken advantage of during phase partitioning, 
by overlaying the sample on a 6% sucrose cushion containing 150 mM NaCl, 0.06% Triton X-
114 in 10 mM Tris-Hcl buffer [pH 7.4] and centrifugation at 300g for 3 minutes at room 
temperature; wherein, the hydrophilic proteins emerge in the aqueous phase while the 
amphiphilic, integral membrane proteins are found in the detergent phase [88].  
2.5 Akita cells 
 Akita cell line was provided by Prof. Sasanka Ramanadham, University of Alabama, 
Birmingham, AL. Akita and wild type cells were maintained in DMEM medium prepared with 
17.5% heat-inactivated FBS, with antibiotic preparation [100 IU/ml penicillin and streptomycin] 
and 2-mercaptoethanol. The cultured cells were harvested and lysed in RIPA buffer containing 
protease inhibitor cocktail, 1 mM NaF, 1 mM PMSF and 1 mM Na3VO4. 
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2.6 Western Blotting 
 Cell lysate proteins [30-50 µg loaded per lane] were subjected to SDS-Polyacrylamide 
gel electrophoresis and electro transferred onto a nitrocellulose membrane. The membranes 
were blocked with 5% non-fat dry milk in 10 mM Tris–HCl, pH 7.6, 1.5 M NaCl and 0.1% Tween 
20 [TBS-T] followed  by incubation with primary antibodies in TBS-T containing 5% BSA at room 
temperature for 1 hr and washed 5X for 5 min each with TBS-T. The membrane was then 
incubated with corresponding secondary antibodies conjugated to horseradish peroxidase 
[1:1000] in 5 % non-fat dry milk in TBS-T at room temperature for 1 hr. After washing the blots in 
TBS-T again, the signal for proteins on the blots was enhanced using 
electrochemiluminescence [ECL] and the images of the blots were developed using Kodak Pro 
Image 400 R [New Haven, CT]. To ensure uniform protein loading and efficient transfer onto the 
membrane, the blots were stripped and re-probed with antibody raised against β actin. Intensity 
of protein bands was quantified by using Carestream Molecular Imaging Software to measure 
the band density. Ratios of band densities of proteins of interest with β actin were calculated 
and expressed as fold change values. 
2.7 Measurement of lamin A and B degradation 
 Following treatment with low glucose [2.5 mM], high glucose [20 mM] or inhibitors [as 
indicated in the text], INS-1 832/13 cells, isolated rat or human islets were lysed in RIPA buffer 
supplemented with 1mM PMSF, 10 μg/mL leupeptin, 10 μg/mL aprotinin, 5 mM EGTA, 5 mM 
EDTA, 10 mM NaF and 1 mM sodium orthovanadate. The samples were clarified by incubating 
on ice for 15 min followed by centrifugation at 14000 rpm for 15 min. The supernatants were 
collected and subjected to a protein estimation assay using Pierce 660 nm protein assay 
reagent. Equal amounts of protein were loaded and separated by SDS-PAGE. Resolved 
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proteins were transferred onto nitrocellulose membrane and probed for lamin B or cleaved lamin 
A as indicated in text, followed by re-probing with β actin. Intensity of protein bands was 
quantified by using Carestream Molecular Imaging Software to measure the band density. 
Ratios of band densities of degraded lamin B and cleaved lamin A with β actin were calculated 
and expressed as fold change values in lamin A or B degradation. 
2.8 Activation of caspase 3 and 6 
 Cells treated with low and high glucose or other stimulants/inhibitors [as indicated in the 
text]. Lysate proteins were subjected to Western blotting. Activation of caspases was estimated 
by the appearance of the bands of cleaved [active] hydrolytic product at 17 and 18 kDa for 
caspase 3 and 6 respectively.  
2.9 Cell viability assay 
 INS-1 832/13 cells were cultured in 96-well plates and treated with low glucose [2.5 mM] 
in the absence or presence of Simvastatin or FTI-277 [10 µM]. After 24 hrs cell viability was 
assessed by using a colorimetric assay with MTT [tetrazolium salt] which measures the 
reduction of the tetrazolium salt into the purple formazan crystals at 570 nm. 
2.10 Insulin release studies 
 Insulin secretion experiments were performed in static incubation conditions. INS-1 
832/13 cells were incubated in the presence of low or high glucose. After 24 hrs, the cells were 
incubated with KRB buffer for 1 hr, prior to stimulation with low or high glucose for 45 min at 
37°C. Insulin secreted by the cells into the medium was detected and measured by ELISA.
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2.11 Cell morphology studies 
 Observation of cell morphology was carried out using an Olympus IX71 microscope. 
INS-1 832/13 cells, incubated overnight in RPMI containing low glucose and 2.5% FBS, were 
treated the following day with media containing low glucose [2.5 mM] alone and in the presence 
of diluent [DMSO], FTI-277 [10 µM] or Simvastatin [15 and 30 µM]. Changes in cell morphology 
were visualized by light microscopy after 24 hrs. 
2.12 Statistical analysis of experimental data 
 Data are represented as Mean ± SEM values. The statistical significance of the 
differences in values between the experimental conditions was established by either Student’s t-
test or ANOVA followed by SNK Post-Hoc test where appropriate.  P value < 0.05 was 
considered significant. 
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CHAPTER 3 
MITOCHONDRIAL DYSFUNCTION INDUCED BY GLUCOTOXIC AND DIABETIC 
CONDITIONS RESULTS IN CASPASE MEDIATED LAMIN DEGRADATION IN 
PANCREATIC BETA CELLS 
Portions of this work have been published [copies of the published manuscripts are appended] 
 
 Khadija S, Veluthakal R, Sidarala V, Kowluru A. Glucotoxic and diabetic conditions induce 
caspase 6-mediated degradation of nuclear lamin A in human islets, rodent islets and INS-1 
832/13 cells. Apoptosis. 2014; 19[12]:1691-701.  
 Syeda K, Mohammed AM, Arora DK, Kowluru A. Glucotoxic conditions induce endoplasmic 
reticulum stress to cause caspase 3 mediated lamin B degradation in pancreatic β-cells: 
protection by nifedipine. Biochem Pharmacol. 2013 1;86[9]:1338-46.  
 
The interior of the nuclear envelope is lined by the nuclear lamina which is composed of 
three proteins; lamins A, B and C. The A type lamins, which include lamins A and C, are 
products of alternative splicing of the same gene LMNA whereas lamin B is encoded by the 
LMNB1 gene [21]. These lamins are type V intermediate filament proteins and are lined up on 
the inner face of the inner nuclear membrane. The nuclear lamina is a fundamental part of major 
nuclear activities, namely mitosis, chromatin organization and in DNA replication. Lamins also 
play key functional roles in providing structural support, thereby contributing to the nuclear 
architecture [89]. Evidence in multiple cell types suggests significant alterations in nuclear 
structure and organization during apoptosis [62]. Some of these include accelerated 
degradation of nuclear lamins A, B and C by executioner caspases 3 and 6 leading to defective 
nuclear assembly and mistargeting of constituents of nuclear lamina to improper subcellular 
compartments [e.g., cytosol]. Degradation of lamins leads to the breakdown of nuclear lamina 
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which is a preliminary stage of apoptosis as this is followed by DNA degradation and chromatin 
condensation [80].  
Previous results from our laboratory indicated that IL-1β treatment causes an increase in 
lamin B degradation mediated by caspases [90]. In addition, a recent study highlighted the 
involvement of caspase 3 in the breakdown of the nuclear matrix by cleaving nuclear lamin B. It 
has been stated that this cleavage probably occurs by activation of caspase 3 directly or by 
other downstream proteases [91]. Recent evidence in PC12 and rat cortical cells also implicates 
cell apoptosis via caspase 3 activation and cleavage of lamin B under lipotoxic conditions 
induced by saturated fatty acids, such as palmitic acid [92].  
The overall objective of this study, therefore, is to investigate the role of caspases on the 
degradation of nuclear lamins, specifically lamin A and B in insulin secreting INS-1 832/13 cells, 
rodent and human islets under high glucose exposure. 
Exposure to glucotoxic conditions cause caspase 3-mediated degradation of lamin B in 
INS-1 832/13 cells 
At the outset, INS-1 832/13 cells were incubated with either low [2.5 mM] or high [20 
mM] glucose for 12, 24 and 48 hrs, and caspase 3 activation, as evidenced by the emergence 
of caspase 3 degradation fragment, was monitored by Western blotting, and the data were then 
quantified by densitometry. Data depicted in Figure 3-1 demonstrate a marked increase in 
caspase 3 activation as early as 12 hrs [1.8-fold; Panel A], which continued to increase as a 
function of time [2.2- and 2.6-fold increase at 24 and 48 hrs, respectively; Panels B and C]. 
Furthermore, we noticed a marked increase in the degradation of lamin B under these 
conditions [Figure 3-1]. For example the fold increase in lamin B degradation represented 1.6-
fold at 12 hrs [Panel A], 1.8-fold at 24 hrs [Panel B] and 2.3-fold at 48 hrs [Panel C]. Panels D 
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and E depict combined data from multiple experiments. Together, data in Figure 3-1 suggest 
activation of caspase 3 and degradation of lamin B under glucotoxic conditions. It should be 
noted that the observed effects of glucose on caspase 3 activation and lamin B degradation are 
not due to osmotic effects of glucose since incubation of these cells with mannitol [20 mM], used 
as an osmotic control, did not elicit any effects on caspase 3 activation and lamin B degradation 
under these conditions [n = 2 experiments; additional data not shown].  
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Figure 3-1: Exposure of INS-1 832/13 cells to glucotoxic conditions results in caspase 3 
activation and lamin B degradation. INS-1 832/13 cells were incubated in the presence of low 
[2.5 mM] or high [20 mM] glucose for 12 hrs [Panel A], 24 hrs [Panel B], and 48 hrs [Panel C], 
and protein lysates [~50 μg] were resolved by SDS-PAGE and transferred to a nitrocellulose 
membrane. Cleaved caspase 3 and lamin B antibodies were used to probe the membrane and 
immune complexes were identified using ECL. To ensure equal protein loading, the same 
membranes were reprobed with antisera against β-actin. Band-intensity of proteins was 
quantified by densitometry. T-test was used to measure the statistical significance of the 
differences in values between the control and experimental conditions. Data in Panel D and E 
represent mean ± SEM from three to four independent experiments and expressed as fold 
change in caspase 3 activation and lamin B degradation. *P < 0.05 vs. 2.5 mM glucose. 
Caspase 6 activation and cleavage of lamin A in INS-1 832/13 cells treated with high 
glucose 
Further, we wanted to examine if exposure of INS-1 832/13 cells to glucotoxic conditions 
would result in activation of caspase 6 and associated degradation of lamin A. Data in Figure 3-
2 [Panel A] represent a Western blot from one of these experiments, which indicates a 
significant increase in caspase 6 activity in high glucose-treated cells as evidenced by 
emergence of a cleaved 18 kDa biologically active peptide of caspase 6. Furthermore, we 
noticed a corresponding increase in the abundance of a 28 kDa lamin A degradation product in 
lysates derived from cells exposed to high glucose. Panels B and C depict data accumulated 
from multiple experiments.  
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Figure 3-2: Caspase 6 activation and lamin A cleavage in INS-1 832/13 cells treated with high 
glucose. INS-1 832/13 cells were incubated in the presence of low or high glucose for 24 hrs. 
Caspase 6 activation and lamin A cleavage were determined by Western blotting. Protein 
lysates [~40 µg] were loaded onto SDS-Polyacrylamide gels and transferred onto a 
nitrocellulose membrane. Antibodies against cleaved caspase 6 and cleaved lamin A were 
utilized to probe the membrane and immune complexes were identified using ECL detection kit 
[Panel A]. After stripping the membranes, they were re-probed with β-actin antibody to ensure 
uniform loading of proteins. Band-intensity of proteins was evaluated by densitometry. Data 
represent mean ± SEM from three independent experiments and expressed as fold change in 
caspase 6 [Panel B] and lamin A cleavage [Panel C]. *P < 0.05 vs. 2.5 mM glucose. 
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Chronic glucose exposure significantly impairs GSIS in INS-1 832/13 cells 
Several lines of evidence suggest that exposure of pancreatic beta cells to 
hyperglycemic conditions leads to the onset of metabolic stress, loss in glucose-stimulated 
insulin secretion [GSIS] and cell demise. Therefore, in the next set of studies, we quantified 
effects of high glucose exposure [20 mM; 24 hrs] on GSIS using the INS-1 832/13 cell line. Data 
in Figure 3-3 indicate a significant increase [~ 2 fold] in basal secretion from these cells 
following exposure to glucotoxic conditions; [bar 1 vs. 3]. In addition, insulin secretion elicited by 
stimulatory glucose concentrations decreased significantly in these cells exposed to glucotoxic 
conditions [bar 2 vs. 4]. These data indicate significant impairment in GSIS in INS-1 832/13 cells 
after 24 hrs of incubation in media containing high glucose. 
 
Figure 3-3: Glucotoxic conditions attenuate GSIS in INS-1 832/13 beta cells. INS-1 832/13 cells 
were cultured in the presence of low and high [2.5 and 20 mM] glucose. After 24 hrs they were 
stimulated with low or high glucose for 45 min. Amount of Insulin released into the culture 
medium was evaluated by ELISA [see Methods-section 2.7 for additional details]. The data are 
expressed as insulin release [ng/ml] and are means ± SEM from three independent 
experiments. *P < 0.05 vs. 2.5 mM glucose under 24 hrs low glucose treatment; **P < 0.05 vs. 
20 mM glucose under 24 hrs low glucose treatment. 
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Glucotoxic conditions induce caspase 3 and 6 activation and subsequent degradation of 
lamin A and B in normal rat islets 
Based on the above observations and our findings on caspase 3 and 6 activation and 
lamin A and B degradation under glucotoxic conditions, we repeated these studies in primary rat 
islets to further validate the observed effects of glucotoxicity on caspase activation and lamin 
degradation. Data depicted in Figure 3-4 indicate an increase in caspase 3 and 6 activation 
followed by a corresponding increase in lamin A and B degradation under these conditions 
[Figure 3-4; Panels A and D]. Panels B,C and E,F display data combined from multiple 
experiments.   
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Figure 3-4: Treatment of normal rat islets with high glucose results in caspase 3 and 6 activation 
and hydrolytic cleavage of downstream substrates: lamins A and B. Rat islets were incubated in 
the presence of low [2.5 mM] and high glucose [20 mM] for 24 hrs. Approximately 40 µg protein 
lysates from each condition were resolved by SDS-PAGE and the degree of abundance of 
cleaved caspase 3 and lamin B [Panel A] and cleaved caspase 6 and lamin A [Panel D] were 
determined by Western blot analysis. The loading control used was β-actin. Quantitation of 
caspase activation and lamin degradation were carried out by densitometry. Data represent 
mean ± SEM from three independent experiments and are expressed as fold change in cleaved 
caspase 3 [Panel B], degraded lamin B [Panel C], cleaved caspase 6 [Panel E] and cleaved 
lamin A [Panel F].  *P < 0.05 vs. 2.5 mM glucose. 
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Increased activation of caspases and associated degradation of lamins are also 
demonstrable in human islets treated with high glucose 
As a logical extension of the above studies, we quantified caspase activation and lamin 
degradation in islets obtained from human donors. We noticed a 1.9-fold increase in caspase 3 
activation and 2-fold increase in lamin B degradation; likewise we also observed a 2.17-fold and 
a 1.69-fold increase in active caspase 6 and cleaved lamin A respectively in human islet 
preparations incubated with high glucose [30 mM; 24 hrs; Figure 3-5; Panels A-D]. These data 
further support our observations in INS-1 832/13 cells, suggesting that a similar mechanism of 
beta cell death may be operable in primary islets [rat and human] [Figure 3-1 and 3-2]. 
 
Figure 3-5: Glucotoxic conditions promote caspase 3 and 6 activation and nuclear lamina 
breakdown in normal human islets treated with high glucose. Normal human islets were 
incubated in the presence of low [5.8 mM] and high glucose [30 mM] for 24 hrs as described in 
the text. 25 µg Lysate proteins were loaded onto SDS-Polyacrylamide gels and then transferred 
to nitrocellulose membranes. The membranes were probed for cleaved caspases 3 and 6, and 
lamin A and B and immune complexes were identified using ECL detection kit. To ensure equal 
protein loading, the same membrane was re-probed using antibody for β-actin. Human islet data 
were accrued from a single batch of islet preparation.  
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Evidence for expression of ZMPSTE24 [a zinc metallopeptidase responsible for 
endoproteolytic cleavage of pre-lamin A to mature lamin A] in INS-1 832/13 cells and 
human islets 
 Mature lamin A is synthesized as prelamin A, the precursor form, which subsequently 
undergoes post-translational modifications, including farnesylation and carboxylmethylation. The 
modified form of prelamin A is subsequently cleaved by the enzyme ZMPSTE24, a zinc 
metallopeptidase, which detaches 15 amino acids from the carboxyl end, thereby releasing 
mature lamin A [39]. Earlier studies from our laboratory have demonstrated carboxylmethylation 
of lamins in islet beta cells [45]. Therefore, in the last set of studies we asked if ZMPSTE24 is 
expressed in the islet beta cells, and whether glucotoxic conditions affect the expression of this 
peptidase. Data depicted in Figure 3-6 provide evidence for the expression of ZMPSTE24 in 
INS-1 832/13 cells [Panel A] and human islets [Panel C]. Furthermore, we noticed no significant 
effects of glucotoxic conditions on the expression of this protein in the two cell types studied 
[Panel A–C], suggesting that proteolytic processing of lamin A may not be affected under 
glucotoxic conditions. 
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Figure 3-6: ZMPSTE 24 is expressed in INS-1 832/13 cells and normal human islets. Lack of 
effects of high glucose exposure on the expression of ZMPSTE 24. INS-1 832/13 cells were 
incubated in the presence of low [2.5 mM] or high [20 mM] glucose. After 24 hrs protein lysates 
were resolved by SDSPAGE and transferred to a nitrocellulose membrane. Panel A shows a 
representative blot from three studies. Intensity of protein bands was quantified by densitometry 
and data represent mean ± SEM from three independent experiments and are expressed as 
fold change in ZMPSTE 24 [Panel B]. NS not significant vs. 2.5 mM glucose. Normal human 
islets were incubated in the presence of low [5.8 mM] and high glucose [30 mM] for 24 hrs [as in 
Figure 3-5]. 25 µg of islet lysate proteins were loaded onto a SDS-Polyacrylamide gel and 
transferred to a nitrocellulose membrane. The membranes were probed with Antisera against 
ZMPSTE 24 and the protein was detected using ECL kit. To ensure equal protein loading, the 
membranes were probed for β actin. A blot from a single human islet preparation is shown in 
Panel C. 
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Alterations in the subcellular distribution of cleaved caspase 3 and lamin B in INS-1 
832/13 cells exposed to glucotoxic conditions 
In these studies, we determined potential alterations, if any, in the subcellular 
localization of active caspase 3 fragment and lamin B degradation products in INS-1 832/13 
cells following exposure to glucotoxic conditions. To determine this, INS-1 832/13 cells were 
incubated for 24 hrs with low or high glucose [2.5 or 20 mM]. Individual subcellular fractions, 
namely the cytosolic fraction [fraction F1], membrane/organelle protein fraction [fraction F2] and 
the pure nucleic protein fraction [fraction F3] were isolated using a ProteoExtract subcellular 
proteome extraction kit [Materials and Methods- Section 2.3]. At the outset, we determined 
subcellular distribution of native caspase [pro-caspase] and lamin B in INS-1 832/13 lysates. 
Data depicted in Figure 3-7 [Panel A], as expected, suggest that native lamin B and pro-
caspase are localized predominantly in the nuclear [F3] and cytosolic [F1] fractions, 
respectively. However, glucotoxic conditions caused significant alterations in the subcellular 
distribution of biologically active [cleaved] caspase 3 and degraded lamin B [Figure 3-7; Panel 
B]. For example, we noticed significant accumulation of degraded lamin B in cytosolic [F1] and 
membrane/ organelle protein [F2] fractions under high glucose-treatment conditions. 
Interestingly, we also noticed significant accumulation of cleaved caspase 3 in these fractions. 
Together, these observations demonstrate abnormal distribution of lamin B under glucotoxic 
conditions further suggestive of disassembly of nuclear structure under these conditions. 
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Figure 3-7: Exposure to high glucose results in altered subcellular distribution of caspase 3 and 
degraded product of lamin B in INS-1 832/13 cells. INS-1 832/13 cells were subjected to 
subcellular fractionation using ProteoExtract Subcellular Proteome Extraction Kit at basal level 
[Panel A] and after treatment with low [2.5 mM] and high [20 mM] glucose for 24 hrs [Panel B]. 
20–30 μg of lysate proteins were loaded onto a SDS-Polyacrylamide gel and transferred to a 
nitrocellulose membrane. Lamin B, pro-caspase [Panel A] and cleaved caspase 3 and degraded 
lamin B [Panel B] were detected using antibodies against each protein. Data are representative 
of two experiments with identical results. 
Increased activation of caspases and associated degradation of lamins are also 
demonstrable in diabetic rat islets and in islets from human donors with type 2 diabetes 
 As an extension to the above studies, we quantified caspase 3 and 6 activity and lamin 
A and B degradation in islets derived from the ZDF rat, a known animal model for T2D and in 
islets obtained from human donors with Type 2 diabetes. Islets from age-matched ZLC rats 
were used as controls in these studies. Data in Figure 3-8 represent a Western blot study 
demonstrating a significant increase in the activation of caspase 3 and degradation of lamin B 
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[Panel A] and activation of caspase 6 [Panel D] and cleavage of lamin A [Panel E]  in islets from 
the ZDF rat compared to the ZLC rat islets. Pooled data in islets from multiple ZLC and ZDF rats 
are given in Panels B, C, F and G. Compatible with our findings above, we also noticed a 
marked increase in lamin A and B degradation in islets from a human donor with T2DM along 
with activation of caspases depicted in Figure 3-9 [Panel A and B]. T2D human islets studies 
were performed using single islet preparation. 
  ZLC 
Mean ± SEM
ZDF 
Mean ± SEM 
Body Weight [g] 275 ± 8 365 ± 7 
Blood Glucose [mg/dl] 80 ± 12 276 ± 37 
Table 3-1: Body weights and blood glucose levels of ZLC and ZDF rats measured at the time of 
sacrifice.  
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Figure 3-8: Activation of caspase and lamin degradation are observed in islets obtained from 
ZDF rats. Islets isolated from ZDF and ZLC rats by collagenase digestion method were lysed 
using RIPA buffer. Lysate proteins [40 µg] were resolved by SDS-PAGE and the abundance of 
cleaved caspase 3 and 6 and lamin A and B were determined by Western blotting.  To assess 
equal protein loading, the membrane was probed for β-actin. Representative blots from three to 
four ZLC and ZDF islet preparations are shown in Panel A, D and E. Intensity of protein bands 
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was quantified by densitometry and data represent mean ± SEM from three to four islet 
preparations and are expressed as fold change in cleaved caspase 3 [Panel B], degraded lamin 
B [Panel C], cleaved caspase 6 [Panel F] and lamin A [Panel G]. *P < 0.05 vs. ZLC 
 
Figure 3-9: Caspase 3 and 6 activation and lamin A and B degradation in diabetic human islets. 
Islets obtained from normal and diabetic individuals were lysed using RIPA buffer. Proteins from 
cell lysates were separated by gel electrophoresis and transferred to a nitrocellulose membrane. 
Cleaved caspase 3 and 6, and lamin A and B and β-actin antibodies were used to probe the 
same membrane after stripping. Human islet data from normal and diabetic individuals were 
accrued from a single batch of islet preparation. 
 
Collectively, data shown in Figures 3-1 to 3-9 can be summarized as follows: 
 Glucotoxic conditions promote the activation of executioner caspases 3 and 6, which 
leads to the degradation of their downstream targets, the nuclear lamins A and B in INS-
1 832/13 cells, normal rodent and human islets. 
 Evidence of the expression of ZMPSTE24, a lamin A processing enzyme, was seen in 
INS-1 832/13 cells and human islets. 
Degraded Lamin B
Cleaved Caspase 3
Con         T2D
‐actin
A
Con          T2D 
‐actin
Cleaved Caspase 6 
Cleaved Lamin A
C
Fold Change(Cleaved 
Caspase 3/Actin)
Fold Change (Degraded 
Lamin B/Actin)
Control T2D Control T2D
1.0 1.41 1.0 1.71
Fold Change (Cleaved 
Caspase 6/Actin)
Fold Change (Cleaved 
Lamin A/Actin)
Control T2D Control T2D
1.0 1.43 1.0 1.36
B
D
54 
 
 
 
 Under conditions of high glucose exposure, a significant impairment in the insulin 
secretion capacity of the beta cells was observed. 
 Significant alterations in the subcellular distribution of lamin B were observed under 
glucotoxic conditions. 
 Islets obtained from the ZDF rat, a model for T2D and islets from T2D human donors 
also exhibit similar effects on activation of caspases and proteolytic cleavage of lamins.
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CHAPTER 4 
IDENTIFICATION OF DOWNSTREAM SIGNALING EVENTS INVOLVED IN 
GLUCOTOXICITY INDUCED ENDOPLASMIC RETICULUM [ER] STRESS LEADING 
TO DYSFUNCTION IN PANCREATIC BETA CELLS 
Portions of this work have been published [copies of the published manuscripts are appended] 
 
 Khadija S, Veluthakal R, Sidarala V, Kowluru A. Glucotoxic and diabetic conditions induce 
caspase 6-mediated degradation of nuclear lamin A in human islets, rodent islets and INS-1 
832/13 cells. Apoptosis. 2014; 19[12]:1691-701.  
 Syeda K, Mohammed AM, Arora DK, Kowluru A. Glucotoxic conditions induce endoplasmic 
reticulum stress to cause caspase 3 mediated lamin B degradation in pancreatic β-cells: 
protection by nifedipine. Biochem Pharmacol. 2013 1;86[9]:1338-46.  
 
Thapsigargin, a known inducer of ER stress, markedly increases caspase 3 activation 
and lamin B degradation in INS 1-832/13 cells 
 
Figure 4-1: Chemical Structure of Thapsigargin 
 Several lines of experimental evidence implicate ER stress as one of intermediate steps 
involved in glucotoxicity of the islet beta cell [93]. To determine if high glucose induces ER 
stress in our current experimental model, we quantified CHOP expression, an ER stress marker, 
in INS-1 832/13 cells exposed to low and high glucose conditions. Data depicted in Figure 4-2 
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[Panel A] demonstrate a significant increase in CHOP expression in cells exposed to glucotoxic 
conditions and a similar result was obtained with thapsigargin [Panel B]. To further assess if ER 
stress induces caspase 3 activation and lamin B degradation, we incubated INS-1 832/13 cells 
with thapsigargin and then quantitated caspase 3 activation and lamin B degradation in these 
cells. Data depicted in Figure 4-2, Panel E demonstrate significant increase in caspase 3 
activation in cells treated with thapsigargin as early as 2 hrs of incubation [3.4- fold; Figure 4-2 
Panels E and F]. Note that thapsigargin effects were maximal at 2 hrs since no further increase 
in caspase 3 activation was seen at 4 hrs [3.1-fold activation] and 6 hrs [3-fold activation; Panels 
E and F]. Under these conditions, we also noticed a significant increase in lamin B degradation 
induced by thapsigargin within 2 hrs [1.9-fold], which remain plateaued at 4 hrs [1.8- fold] and 6 
hrs [1.7-fold] as shown in Panels E and G. Together, our findings suggest ER stress as one of 
the mechanisms underlying glucose-mediated effects on caspase 3 activation and lamin B 
degradation. In the next set of studies, we further tested this hypothesis using a 
pharmacological approach. 
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Figure 4-2: Thapsigargin, a known inducer of ER stress, also promotes caspase 3 activation 
and lamin B degradation in INS-1 832/13 cells. Cells were incubated with low glucose [2.5 mM] 
or high glucose [20 mM] for 24 hrs. Expression of CHOP was determined in cell lysates by 
Western blotting [Panel A]. The same membranes were reprobed using antibody against β-
actin. Densitometry was used to measure CHOP expression. The statistical significance of the 
differences between the control and the experimental groups was determined by t-test. Panel C 
represents data from three independent experiments. *P < 0.05 vs. 2.5 mM glucose. Panel B: 
INS-1 832/13 cells were incubated with low glucose [2.5 mM] or thapsigargin [Tg; 0.25 μM for 6 
hrs]. Expression of CHOP was determined by Western blotting. Uniform protein loading was 
assessed by re-probing the same membrane with antiserum against β-actin. Quantification of 
CHOP expression was carried out by densitometry. The statistical significance of the differences 
in Mean ± SEM values between the control and the experimental groups was evaluated by 
student’s t-test. Data in panel D represent mean ± SEM from three independent experiments 
and expressed as fold change. *P < 0.05 vs. 2.5 mM glucose. Panel E: INS-1 832/13 cells were 
treated with low glucose [2.5 mM] or thapsigargin [Tg; 0.25 µM] for 2, 4 and 6 hrs as indicated in 
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the figure. Lysate proteins were loaded onto a SDS-Polyacrylamide gel and electro-transferred 
onto a nitrocellulose membrane. The membrane was probed with antisera against cleaved 
caspase 3 and degraded lamin B. To ascertain uniform loading of proteins, the membrane was 
stripped and reprobed with antibody against β-actin. Quantification of caspase 3 activation and 
lamin B degradation were carried out by densitometry. Data in Panel E and F represent mean ± 
SEM from three independent experiments and expressed as fold change. *P < 0.05 vs. 2.5 mM 
glucose. 
Caspase 3 activation and Lamin B degradation observed in Akita beta cells: an ER stress 
mouse model 
The Akita mouse model has a spontaneous mutation in the Ins2 gene, which causes 
misfolding of the translated insulin in the endoplasmic reticulum. Therefore, Ins2Akita mice serve 
as a suitable model for ER stress in the beta cell, seen in diabetic conditions.  They develop 
insulin dependent diabetes, including hyperglycemia, hypoinsulinemia, polydipsia, and polyuria. 
We wanted to examine if the effects on caspase 3 and lamin B seen under glucotoxic conditions 
could be mimicked in cells obtained from Akita mice in order to decipher the role of ER stress in 
our model. Results acquired from a Western blot study, after running the lysates obtained from 
wild type [WT] and Akita cells, are depicted in Figure 4-3. We observed a higher level of active 
caspase 3 and degradation of lamin B in cells from the Akita mouse compared to the wild type. 
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Figure 4-3: Akita mouse cells show noticeable caspase 3 activation and lamin B degradation. 
Lysate proteins from Akita and WT cells were resolved by gel electrophoresis, and then electro-
transferred onto a nitrocellulose membrane. The abundance of cleaved caspase 3 and lamin B 
were determined by Western blotting.  Equal protein loading was ensured by reprobing the 
membrane with antibody against β-actin.  
 
4-Phenylbutyric acid [PBA], a known inhibitor of ER-stress, markedly attenuates glucose-
induced CHOP expression, caspase 3 activation and lamin B degradation 
 
Figure 4-4: Chemical Structure of PBA 
As a logical extension to the above studies, we attempted to establish a causal role for 
ER-stress in high glucose-induced caspase 3 activation and lamin B degradation. To 
accomplish this, we used PBA [Figure 4-4], a known inhibitor of ER-stress, on glucose-induced 
caspase 3 activation and lamin B degradation. We also quantified CHOP expression in these 
cells to affirm that PBA inhibits glucose-induced ER-stress under current experimental 
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conditions. Data depicted in Figure 4-5 demonstrate a significant increase in CHOP expression 
in glucose-treated cells. We also observed complete inhibition of glucose-induced CHOP 
expression by PBA [Figure 4-5, Panel A]. These data thus validate the use of PBA as an 
inhibitor of ER-stress in INS-1 832/13 cells. More importantly, we also noticed a complete 
inhibition of glucose-induced caspase 3 activation and lamin B degradation by PBA in these 
cells [Figure 4-5; Panel B]. Taken together, these data provide the first evidence that 
glucotoxicity promotes caspase 3 activation and lamin B degradation in an ER-stress sensitive 
fashion. 
 
Figure 4-5: PBA, a known inhibitor of ER-stress, markedly attenuates glucose-induced CHOP 
expression, caspase 3 activation and lamin B degradation in INS-1 832/13 cells. Cells were 
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incubated in the presence of low or high [2.5 or 20 mM] glucose for 24 hrs in the presence and 
absence of PBA [0.5 mM]. Approximately 40 μg protein lysates were loaded onto SDS-
Polyacrylamide gels and electro-transferred onto nitrocellulose membranes. The membranes 
were probed with antibodies against CHOP [Panel A], active caspase 3 and degraded lamin B 
[Panel B]. Uniform protein loading was assessed by reprobing the membranes antibody against 
β-actin. Intensity of protein bands was quantified by densitometry [Panels C-E]. Data represent 
mean ± SEM from three independent experiments and expressed as fold change in CHOP 
expression, caspase 3 activation and lamin B degradation. *P < 0.05 vs. 2.5 mM glucose 
without inhibitor, #P < 0.05 vs. 20 mM glucose without inhibitor. 
Nifedipine, a calcium channel blocker, inhibits glucose-induced caspase 3 activation and 
lamin B degradation in INS-1 832/13 cells 
 
Figure 4-6: Chemical Structure of Nifedipine 
We recently reported that calcium overload may represent one of the signaling 
mechanisms involved in caspase-3 activation under conditions of cellular apoptosis in isolated 
beta cells. For example, using etoposide, a known inducer of loss in metabolic viability in beta 
cells, we reported a marked increase in caspase 3 activity in INS-1 832/13 cells and normal rat 
islets. More importantly, we have been able to prevent etoposide-induced metabolic dysfunction 
in these cells by nifedipine [Figure 4-6], a known blocker of L-type calcium channel activation 
and calcium entry [93]. Furthermore, recent findings from the laboratory of Wang and 
associates [94] have also demonstrated significant protective effects of nifedipine against high 
glucose-induced ER stress and apoptosis. Therefore, as a logical extension to findings that we 
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reported above, we undertook a study to see if glucose-induced caspase 3 activation and lamin 
B degradation are prevented by nifedipine. Data presented in Figure 4-7, Panel A indicate a 
modest, but insignificant [1.2-fold] increase in caspase 3 activation in INS-1 832/13 cells 
incubated with nifedipine alone under basal conditions. No significant effects of nifedipine were 
demonstrable on lamin B degradation under these conditions. As shown above, high glucose-
treatment markedly enhanced caspase 3 activation [2.5- fold] and lamin B degradation [1.9-fold; 
Figure 4-7, Panels B and C]. Interestingly, co-provision of nifedipine with glucose markedly 
reduced high glucose-induced effects on caspase 3 activation [2.5-fold vs. 1.2- fold in the 
absence and presence of nifedipine, respectively]. In a manner akin to these findings, nifedipine 
also attenuated lamin B degradation induced by glucose [1.9-fold in the absence of nifedipine 
and 1.2-fold in its presence; Figure 4-7]. 
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Figure 4-7: Nifedipine, a calcium channel blocker, inhibits glucose-induced caspase 3 activation 
and lamin B degradation in INS-1 832/13 cells. Panel A: INS-1 832/13 cells were incubated with 
low glucose or high glucose [2.5 or 20 mM] for 24 hrs in the absence [diluent] or presence of 
nifedipine [10 μM]. Proteins obtained after cell lysis were resolved by gel electrophoresis and 
electro-transferred onto a nitrocellulose membrane. The membrane was probed with antibodies 
against cleaved caspase 3 and lamin B. To ensure uniformity in protein loading, the same 
membranes were re-probed with β-actin antibody. Band densities of caspase 3 activation and 
lamin B degradation were measure. Data represent mean ± SEM from three independent 
experiments and expressed as fold change [Panel B and C]. *P < 0.05 vs. 2.5 mM glucose 
without nifedipine and #P < 0.05 vs. 20 mM without nifedipine. 
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Z-DEVD-FMK, a known inhibitor of caspase 3, markedly attenuates high glucose-induced 
caspase 3 activation and lamin B degradation in INS-1 832/13 cells 
In vitro studies on beta cell lines utilizing caspase inhibitors have demonstrated that the 
caspase 2 inhibitor is effective in protecting the HIT-T15 beta cell line against an experimental 
model of cell death [95]. Furthermore, murine TC-1 cell lines transfected with human Fas were 
shown to be protected against Fas-induced beta cell apoptosis by the caspase 3 inhibitor Z-
Asp-Glu-Val-Asp-fluoromethyl ketone [96] and palmitate-induced beta cell apoptosis, could be 
prevented by executioner caspase 6 inhibitors [97]. The preferential recognition of different 
caspases for specific amino acid sequences on the substrate proteins has been taken 
advantage of in the development of specific peptide inhibitors. These caspase inhibitors are cell 
permeable and bind to the active site of the proteases and thereby obstruct the progression of 
apoptotic pathway downstream of caspase activation. In an attempt to investigate the 
dependency of lamin degradation on upstream caspase 3 activation, observed in glucotoxicity 
induced apoptotic signaling, we used a cell permeable peptide inhibitor, specific for caspase 3 
[Z-DEVD-FMK]. We measured lamin B degradation and caspase 3 activation in cells treated 
with low and high glucose conditions in the absence and presence of Z-DEVD-FMK. Data in 
Figure 4-8 Panel A show a marked inhibition of lamin B degradation and caspase 3 activation 
after treatment with the inhibitor. Panels B and C represent data collected from three to four 
experiments. 
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Figure 4-8: Z-DEVD-FMK, a known inhibitor of caspase 3, prevented high glucose induced 
caspase 3 activation and lamin B breakdown in INS-1 832/13 cells. INS-1 832/13 cells were 
preincubated with Z-DEVD-FMK [3μM] for 1 hr and further treated with low [2.5 mM; LG] or high 
[20 mM; HG] glucose in the presence and absence of Z-DEVD-FMK for 6 hrs. Caspase 3 
activation and lamin B degradation [Panel A] were determined by Western blotting. To ensure 
equal protein loading, the membranes were probed with β-actin antiserum. Data represent 
mean ± SEM from three to four independent experiments and expressed as fold change in 
caspase 3 and lamin B degradation [Panel B and C]. *P < 0.05 vs. 2.5 mM glucose in the 
absence of the inhibitor; # P < 0.05 vs. 20 mM glucose without inhibitor. NS: Not significant vs. 
2.5 mM glucose in the absence of the inhibitor. 
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Z-DEVD-FMK significantly reduces high glucose-induced activation of executioner 
caspase 6 and degradation of lamin A in INS-1 832/13 cells 
Evidence in different cell types suggests that event of caspase 3 activation in the 
caspase cascade is upstream to activation of caspase 6 [98], and/or both these executioner 
caspases are cleaved and thereby activated under conditions induced by apoptotic stimuli [99]. 
Therefore, in the next set of experiments, we examined if caspase 3 activation precedes 
caspase 6 activation in beta cells under the duress of glucotoxicity. To address this, we 
quantified caspase 6 activation in INS-1 832/13 cells under high glucose treatment conditions in 
the absence or presence of caspase 3 inhibitor [Z-DEVD-FMK]. Data shown in Figure 4-9 
[Panel A], demonstrate significant inhibition of glucose-induced caspase 6 activation following 
inhibition of caspase 3. Panel B includes data accumulated from multiple experiments. It should 
be noted that caspase 3 inhibitor also activated caspase 6 under low glucose incubation 
conditions. Furthermore, Z-DEVD-FMK significantly attenuated high glucose-induced lamin A 
degradation [Figure 4-9; Panel C], further supporting the notion that glucose-induced caspase 3 
activation might lie upstream to caspase 6 activation and lamin A degradation. Collectively, at 
least, based on our current and recently published findings [100], we conclude that executioner 
caspases [caspase 3 and 6] mediate nuclear lamin [A and B] degradation and chromatin 
condensation and collapse of nuclear envelope under conditions of glucotoxicity.  
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Figure 4-9: Z-DEVD-FMK, a known inhibitor of caspase 3, prevented high glucose induced 
caspase 6 activation and lamin A breakdown in INS-1 832/13 cells. INS-1 832/13 cells were 
preincubated with Z-DEVD-FMK [3μM] for 1 hr and further treated with low [2.5 mM] or high [20 
mM] glucose in the presence and absence of Z-DEVD-FMK for 6 hrs. Caspase 6 activation 
[Panel A] and lamin A cleavage [Panel C] were determined by Western blotting. To check equal 
protein loading, the membranes were probed for β-actin. Data represent mean ± SEM from 
three independent experiments and expressed as fold change in caspase 6 [Panel B] and lamin 
A cleavage [Panel D]. *P < 0.05 vs. 2.5 mM glucose in absence of inhibitor; # P < 0.05 vs. 20 
mM glucose without inhibitor. NS: Not significant vs. 2.5 mM glucose in absence of inhibitor. 
 
Z-VEID-FMK, a known inhibitor of caspase 6, markedly attenuates glucose-induced 
caspase 6 activation and breakdown of lamin A in INS-1 832/13 cells 
 We further investigated the effects of Z-VEID-FMK, a known inhibitor of caspase 6, on 
high glucose-induced caspase 6 activation and lamin A degradation in INS-1 832/13 cells. Data 
in Figure 4-10 [Panel A] represents a Western blot demonstrating directional inhibition of high 
glucose-induced activation of caspase 6 by its inhibitor. It should be noted that we consistently 
observed a modest increase in the caspase 6 activation in cells exposed to its inhibitor under 
low glucose conditions [Figure 4-10; Panel A]. However, data from multiple experiments 
indicated that this increase was not significant [Figure 4-10; Panel B].  Furthermore, Z-VEID-
FMK inhibited high glucose-induced degradation of lamin A under the conditions it inhibited 
caspase 6 [Figure 4-10; Panel C]; these findings provide support to the notion that caspase 6 
does play a contributory role, although not entirely, in the cleavage of lamin A in pancreatic beta 
cells under glucotoxic and diabetic conditions. Figure 4-10; Panel D displays data combined 
from multiple experiments. It should be noted that as in the case of caspase 6 activation, we 
noticed increase in lamin A degradation in INS-1 832/13 cells exposed to caspase 6 inhibitor 
under low glucose treatment conditions. Collectively, our findings implicate a contributory role of 
caspase 6 in lamin A degradation under glucotoxic conditions.  
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Figure 4-10: High glucose-induced caspase 6 activation and breakdown of lamin A cleavage 
were attenuated by Z-VEID-FMK, a specific inhibitor of caspase 6, in INS-1 832/13 cells 
INS-1 832/13 cells were preincubated with Z-VEID-FMK [3μM] for 1 hr and further treated with 
low [2.5 mM] or high [20 mM] glucose in the presence and absence of Z-VEID-FMK for 6 hrs.  
Caspase 6 activation and lamin A cleavage were determined by Western blotting. The 
membrane was probed for cleaved caspase 6 [Panel A] and cleaved lamin A [Panel C], and 
immune complexes were identified using ECL detection kit. To ensure equal protein loading, the 
membranes were probed for β actin. Data represent mean ± SEM from three independent 
experiments and expressed as fold change in caspase 6 [Panel B] and lamin A cleavage [Panel 
D]. *P < 0.05 vs. 2.5 mM glucose without inhibitor. NS: Not significant vs. 2.5 mM glucose 
without inhibitor. 
 
Studies using rottlerin, an inhibitor of PKC-δ, on the activation of caspase 3 and 
degradation of lamin B  
 Several studies have shown that in order for caspases to target the nuclear lamins for 
proteolytic degradation, phosphorylation of the lamin filaments by PKC-δ is required. In an 
attempt to gain deeper insight into this mechanism we tested the effects of rottlerin [5 and 10 
µM], an inhibitor of PKC-δ on lamin B under the duress of glucotoxicity. However we could not 
see an inhibitory effect of this compound on the degradation of lamin B in our experiment in 
INS-1 832/13 cells [Figure 4-11]. Further we also tested siRNA against PKC-δ but could not 
attain sufficiently high transfection efficiency even at 200 nm concentration of the siRNA [data 
not shown]. Since PKC-δ is one of 11 isoforms of the PKC family and has a number of splice 
variants [PKC-δI, PKC-δII] which could be pro-apoptotic or anti-apoptotic [101], it would be 
interesting to study each splice variant individually and identify the role of each distinct splice 
variant in the processing of lamins. 
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Figure 4-11: Rottlerin had no effect on high glucose induced activation of caspase 3 and lamin 
B degradation. INS-1 832/13 cells were preincubated with rottlerin [5 and 10 μM] for 1 hr and 
further treated with low [2.5 mM] or high [20 mM] glucose in the presence and absence of 
rottlerin for 6 hrs.  Activation of executioner caspase 3 and lamin B degradation were examined 
by Western blotting. To ensure equal protein loading, the membranes were probed for β-actin. 
Representative blots from 3 individual experiments are shown in the figure above. 
 
Results obtained from these studies can be summarized as follows: 
 Effects of glucotoxicity on CHOP expression are comparable to those of thapsigargin, a 
potent inducer of ER stress in many cell types. Thapsigargin treatment also induced 
caspase 3 activation and lamin B degradation, as seen under high glucose treatment, 
thereby implicating an ER stress mediated pathway. 
 PBA, an inhibitor of ER stress, markedly reduced glucose-induced CHOP expression, 
caspase 3 activation and lamin B degradation. 
 Blocking of membrane associated L-type calcium ion channels, with nifedipine, markedly 
attenuated high glucose-induced effects on the beta cell.  
 Z-DEVD-FMK, a specific inhibitor of caspase 3, inhibited high glucose-induced caspase 
3, 6 activation and proteolysis of lamin A, B and Z-VEID-FMK, which specifically inhibits 
caspase 6 activation blocked high glucose-induced caspase 6 activation and lamin A 
degradation.  
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CHAPTER 5 
CONSEQUENCES OF INHIBITION OF REQUISITE POST TRANSLATIONAL 
PRENYLATION OF LAMINS ON THE PANCREATIC BETA CELL 
 The nuclear lamins, in their original post transcription stage, are translated as native pre-
lamins, which further need to undergo a series of PTMs and are then processed into their 
mature form for localization into the nuclear membrane, protein interactions and performing their 
functions within the nucleus. Apart from other modifications [Figure 1-5], lamins undergo 
farnesylation at the cysteine residue of the C-terminal CAAX motif [21]. How then, does 
inhibition of prenylation of lamins affect nuclear envelope integrity? What would be the overall 
effects of inhibition of lamin farnesylation on the pancreatic beta cell? To address these 
questions, we made use of pharmacological inhibitors of protein prenylation. Firstly, we used 
simvastatin, which blocks the biosynthesis of mevalonic acid [MVA] and other key intermediates 
in the cholesterol biosynthesis pathway, namely: farnesyl pyrophosphate [FPP] and 
geranylgeranyl pyrophosphate [GGPP], that are involved in post translational prenylation of 
several proteins [Rho, Rab, Ras] [Figure 5-1]. Secondly, we used a farnesyl transferase 
inhibitor, FTI-277, which inhibits the catalytic addition of 15 carbon farnesyl moiety to target 
proteins [e.g., Ras, nuclear lamins]. In addition, we also tested the effects of GGTI-2147, which 
inhibits the enzyme geranylgeranyl transferase [GGTase I]. We examined the effects of these 
inhibitors on the activation of caspase 3, lamin B degradation and overall cell morphology and 
viability in INS-1 832/13 cells and rat islets. 
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Figure 5-1: The cholesterol biosynthesis pathway. The formation of cholesterol begins with 
acetyl CoA and acetoacetyl CoA generating 3-hydroxy 3 methylglutaryl CoA [HMG-CoA], 
followed by a series of steps catalyzed by several enzymes along with generation of a number 
of intermediate metabolites. HMG-CoA reductase, the rate limiting enzyme of this pathway, 
catalyses the synthesis of mevalonate. Simvastatin inhibits the enzyme HMG-CoA reductase, 
thus blocking the subsequent steps which lead to cholesterol biosynthesis. It also prevents the 
formation of metabolites of this pathway, namely: FPP and GGPP that are involved in post 
translational prenylation of several proteins [Rho, Rab, Ras etc.]. FTI-277, inhibits the farnesyl 
transferase enzyme which catalyses the addition of 15 carbon farnesyl moiety to target proteins 
[eg: Ras, nuclear lamins] while GGTI-2147 inhibits GGTase I, therefore blocking 
geranylgeranylation of Rac and Rho. 
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A] Studies on effects of Statins: 
INS-1 832/13 cells and rat islets treated with Simvastatin exhibit increased activation of 
caspase 3 and subsequent degradation of lamin B along with changes in cell 
morphology.  
 At the outset, we treated INS-1 832/13 cells, cultured in RPMI medium, with low glucose 
[2.5 mM] as control and low glucose with Simvastatin [15 μM] for 24 hrs and examined the 
effects of the treatment on caspase 3 and its downstream target lamin B. As shown in Figure 5-
2, Panel A, we observed an increase in cleaved caspase 3, which is an indicator of caspase 3 
activation, and a corresponding increase in the degraded product of lamin B. Pooled data from 3 
independent Western blotting studies, shown in Panels B and C, demonstrate a significant 
increase in band densities of cleaved caspase 3 and degraded lamin B. Along with these 
observations, we also noticed changes in morphology in cells incubated for 24 hrs with 
Simvastatin. Microscopic images in Panel C demonstrate the rounding up of cells treated with 
15 and 30 μM Simvastatin and no visible changes in morphology of cells incubated in media 
containing low glucose alone or with diluent [DMSO].  
 As a logical extension of these experiments we performed the above studies in primary 
cells from rat pancreatic islets. A representative blot from 2 such independent studies is 
depicted in Panel E, wherein islets obtained from normal Sprague Dawley, rats were exposed to 
low glucose in the absence and presence of Simvastatin [15 μM and 30 μM] for 24 hrs. We 
observed a similar increase in caspase 3 activation and lamin B degradation which support our 
observations in INS-1 832/13 cells. 
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Figure 5-2: Exposure of INS-1 832/13 cells, rat pancreatic islets to simvastatin results in 
caspase 3 activation and degradation of lamin B along with changes in cell morphology. 
(A) INS-1 832/13 cells were treated with RPMI media containing 2.5 mM glucose alone and with 
15 μM Simvastatin for 24 hrs. Proteins obtained after cell lysis were resolved by SDS-PAGE 
and electro-transferred onto a nitrocellulose membrane. Antibodies against cleaved caspase 3 
and lamin B were used to probe the membrane. Uniform protein loading was ensured by re-
probing the blots with antibody against β-actin. Student’s t-test was utilized to measure the 
statistical significance of the differences in values between the control and experimental 
conditions. Panel B and C represent mean ± SEM values and are expressed as fold change in 
caspase 3 activation [Panel B] and lamin B degradation [Panel C]. *P < 0.05 vs. 2.5 mM 
glucose. [D] INS-1 832/13 cells, incubated overnight in RPMI medium containing 2.5 mM 
glucose and 2.5% FBS, were treated the following day with media containing low glucose [2.5 
mM] alone and in the presence of diluent [DMSO] or simvastatin [15 μM and 30 μM] for 24 hrs. 
Changes in cell morphology were visualized by light microscopy. [E] Rat islets isolated by 
collagenase digestion method were incubated in media containing low glucose [2.5 mM] in the 
absence and presence of simvastatin [15 μM and 30 μM] for 24 hrs. Activation of executioner 
caspase 3 and lamin B degradation were evaluated by Western blotting. The membrane was re-
blotted with anti β-actin to ensure equal protein loading.  
 
Simvastatin promotes phosphorylation of p38 MAPK and reduces ERK1/2 
phosphorylation in INS-1 832/13 cells 
 In the next set of experiments we examined the effects of Simvastatin treatment on two 
mitogen activated protein kinases [MAPKs] namely, p38 and ERK1/2, both of which are 
regulated by various extracellular stress stimuli and play a critical role in the cell stress 
signaling/survival pathways.   INS-1 832/13 cells were exposed to low glucose [2.5 mM] in the 
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absence and presence of 15 μM simvastatin as described in the previous experiments. Under 
these conditions, we looked for the phosphorylation status of p38 using an antibody specific for 
phospho-p38 and observed a significant increase in the phosphorylated, active form of p38 
MAPK in comparison to the total protein [Figure 5-3 Panel A]. Besides, we also noted a marked 
decrease in ERK1/2 phosphorylation/activation using a monoclonal antibody, which recognizes 
the dual phosphorylation at Thr202 and Tyr204 of ERK1 and Thr185 and Tyr187 of ERK2, as 
shown in Figure 5-3 Panel C. Bar graphs in Panels B and D represents data pooled from 3 
independent experiments and represent fold change in the intensities of the phosphorylated 
protein bands vs. the intensity of total protein levels.  Under the same treatment conditions we 
assessed the metabolic cell viability and found a decrease [~12.4%] in viability with Simvastatin 
treatment [Panel E]. 
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Figure 5-3: Simvastatin treatment causes a marked increase in phosphorylation of p38 MAP 
Kinase and significantly decreases phosphorylation of phospho-p44/42 ERK1/2 and a reduction 
in cell viability. Lysates from INS-1 832/13 cells incubated in RPMI media containing 2.5 mM 
glucose alone and with 15 μM Simvastatin for 24 hrs were resolved by SDS-PAGE and 
transferred to nitrocellulose membranes by wet transfer. The blots were probed for 
phosphorylated p38MAPK and total p38MAPK, phospho-p44/42 ERK1/2 and total p44/42 
ERK1/2. Band densities were calculated by densitometry. Data provided in Panel B and D 
represent mean ± SEM and are expressed as fold change in p38 MAPK phosphorylation [Panel 
B] and p44/42 ERK1/2 phosphorylation [Panel D]. *P < 0.05 vs. 2.5 mM glucose. Panel E; INS-1 
832/13 cells were incubated in low glucose [2.5 mM] in the absence and presence of 
Simvastatin [15 µM]. After 24 hrs cell viability was assessed by the MTT assay. Data are 
represented as mean ± SEM values and are expressed as percent cell viability. *P < 0.05 vs. 
2.5 mM glucose. 
 
B] Studies on effects of FTIs: 
Inhibition of farnesylation with FTI-277 treatment of INS-1 832/13 cells has similar effects 
on lamins as Simvastatin 
 The above effects of simvastatin on lamins and caspases [Figure 5-2], could be due to 
the depletion of FPP and/or GGPP, thereby inhibiting requisite prenylation of key proteins. In 
order to identify the distinct role of geranylgeranylation and farnesylation, we conducted a few 
experiments using inhibitors of each post translational modification. FTI-277 is a specific 
inhibitor of the enzyme FTase, which catalyses the addition of the 15 carbon farnesyl moiety 
onto target proteins e.g., Ras, nuclear Lamins. Herein, we incubated INS-1 832/13 with low 
glucose [2.5 mM] alone and with FTI-277 [10µM] for 24 hrs. Results obtained from these studies 
demonstrated that reduction in the requisite farnesylation of lamin B by exposing cells to FTI-
277 promotes caspase 3 activation and degradation of lamin B [Fig 5-4 Panel A]. Panels B and 
C represent data obtained from three Western blotting experiments. Under the same treatment 
conditions with low glucose in the absence and presence of FTI-277, we performed phase 
partitioning assay using Triton X-114. Here we observed the appearance of the degraded 
fragment of lamin B in the hydrophobic fraction of the membrane component as well as in the 
cytosolic fraction [Panel D]. In addition we assessed the metabolic cell viability by measuring, 
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colorimetrically, the reduction of tetrazolium salt to formazan crystals and found a decrease 
[~12.4%] in viability under these treatment conditions [Panel F]. However these effects were not 
accompanied by any significant changes in cell morphology [Panel E] after 24 hrs of FTI-277 
treatment. 
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Figure 5-4: FTI-277 treatment results in caspase 3 mediated degradation of lamin B along with 
alterations in its subcellular distribution and reduction in cell viability. [A] INS-1 832/13 cells 
were incubated in media containing low glucose [2.5 mM] in the absence and presence of FTI-
277 [10 μM] for 24 hrs. Caspase 3 activation and lamin B degradation for each condition was 
determined by Western blotting. Equal protein loading was ensured by re-probing the 
membrane with anti β-actin. Data represent mean ± SEM from three independent experiments 
and are expressed as fold change in caspase 3 activation [Panel B] and lamin B degradation 
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[Panel C]. *P < 0.05 vs. 2.5 mM glucose. [D] Lysates from INS-1 832/13 cells treated with low 
glucose [2.5 mM] in the absence and presence of FTI-277 [10 µM] were subjected to a single-
step centrifugation to separate the supernatant cytosolic [Cyto] and the membrane-pellet [Mem] 
fractions followed by hydrophobic [HPB] and hydrophilic [HPL] phase partitioning with Triton X-
114 detergent. Proteins obtained after cell lysis were resolved by SDS-PAGE and electro-
transferred onto a nitrocellulose membrane. The membrane was probed for cleaved caspase 3 
and lamin B. [E] INS-1 832/13 cells were treated with media containing low glucose [2.5 mM; 
LG] alone and in the presence of diluent [LG+DMSO], FTI-277 [10 μM] for 24 hrs. Changes in 
cell morphology were visualized by light microscopy. [F] INS-1 832/13 cells were incubated in 
low glucose [2.5 mM] in the absence and presence of FTI-277 [10 µM]. After 24, hrs cell viability 
was assessed by the MTT assay. Data are represented as mean ± SEM values expressed as 
percent cell viability. *P < 0.05 vs. 2.5 mM glucose. 
 
C] Studies on effects of GGTIs: 
GGTI-2147, a geranylgeranyl transferase inhibitor does not exhibit an increase in the 
activation of caspases and degradation of lamins  
 As an extension of the above studies we wanted to study the effect of blocking 
geranylgeranylation on the integrity of the nuclear lamins. To this end, we exposed INS-1 
832/13 cells and primary rat pancreatic islets to GGTI-2147, a specific inhibitor of the enzyme 
GGTase I. A representative blot from 2 such independent studies is depicted in Figure 5-5, 
wherein islets obtained from normal Sprague Dawley rats were exposed to low glucose in the 
absence and presence of GGTI-2147 [10µM] for 24 hrs. Interestingly, blocking of 
geranylgeranylation had minimal effect on the integrity of lamin B and only a slight increase in 
the activation of caspase 3 which point out the possibility that farnesylation of lamins is essential 
for the stability and functioning of these nuclear proteins. 
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Figure 5-5: GGTI-2147 has minimal effects on the integrity of nuclear lamin B and caspase 3. 
INS-1 832/13 cells and rat islets [isolated by collagenase digestion method] were incubated in 
media containing low glucose [2.5 mM] in the absence and presence of GGTI-2147 [10 μM] for 
24 hrs. Western blotting was used to evaluate caspase 3 activation and lamin B degradation. 
The membranes were re-blotted with anti β-actin to ensure equal protein loading.  
 
 Data obtained from the above studies can be summarized as follows: 
 Inhibition of protein prenylation [farnesylation and geranylgeranylation] with simvastatin, 
induced significant alterations in mitochondrial and nuclear stability in pancreatic beta-
cells, as evidenced by activation of executioner caspase-3 and degradation of nuclear 
lamin B, which were also seen in primary rodent islets. 
 Simvastatin mediated blocking of prenylation also resulted in the activation of p38 
MAPK, a stress kinase, which we have recently implicated in islet dysfunction under 
conditions of glucotoxicity and diabetes [102]. In addition, we noticed a marked 
reduction in the phosphorylation of ERK1/2 in simvastatin treated INS-1 832/13 cells, an 
event necessary for G-protein activation, cytoskeletal organization and insulin secretion 
along with loss in cell viability. 
 Results obtained after testing specific inhibitors of FTase [FTI-277] and GGTase-1 
[GGTI-2147] suggest that simvastatin-mediated effects on degradation of lamin B are 
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more likely due to inhibition of farnesylation of lamins [a key step in the processing and 
intracellular localization of lamins] rather than blocking of geranylgeranylation. 
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CHAPTER 6 
DISCUSSION 
 Hyperglycemia in T2DM is a consequence of progressive increase in insulin resistance 
in the peripheral tissues [adipose, muscle] along with decreasing pancreatic beta cell function. 
Several studies indicate that pancreatic islet beta cells, when subjected to glucotoxic and 
lipotoxic environment or when exposed to proinflammatory cytokines [e.g., IL-1β, TNFα and 
IFNγ] exhibit metabolic dysfunction as a result of oxidative and endoplasmic reticulum stress 
[84, 103-105]. A number of potential mechanisms underlying chronic hyperglycemia-induced 
metabolic dysfunction have been put forward, among which oxidative stress as well as 
endoplasmic reticulum stress induced mitochondrial defects and subsequent downstream 
effects are most common [84, 106, 107]. Despite this existing evidence, the precise effects that 
the elevated glucose levels have on the nuclear component of the cell are relatively lesser 
known. Therefore, one of the primary objectives of my doctoral work was to gain mechanistic 
insights into the role of ER-mitochondria axis in the activation of executioner caspases and their 
downstream targets; the nuclear lamins [lamin A and B], in insulin-secreting cells under the 
duress of glucotoxic conditions and diabetes. 
 The nuclear lamins are type V intermediate filament proteins, which assemble in a 
mesh-like pattern, forming the lamina layer within the inner-nuclear membrane. Studies have 
shown that the ER stress-induced effects may have an impact on the integrity of other 
subcellular organelles, such as the mitochondria, resulting in loss of mitochondrial membrane 
permeability transition [MPT] and leakage of cytochrome C into the cytosol [108-111]. Under 
these conditions, executioner caspases [caspase 3 and 6] are activated which then cause the 
hydrolysis of proteins such as PARP, PKC-δ and nuclear lamins. Earlier reports from our own 
laboratory have exhibited a marked augmentation in the degraded product of lamin B as a result 
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of caspase 6 activation in cells subjected to proinflammatory cytokine, IL-1β, treatment. In 
addition there appeared to be an alteration in the distribution of lamin B within the nuclear 
compartment under these conditions [112]. 
 
Figure 6-1: Working model for high glucose-mediated, ER stress-induced beta cell 
damage/dysfunction via caspase 3 mediated degradation of lamin B in pancreatic beta cells. 
Our current findings suggest that glucose-induced metabolic dysfunction in these cells may, in 
part, be due to increase in ER stress. Our model also highlights potential cytoprotective effects 
of calcium channel blockers [e.g., nifedipine], ER stress inhibitors [e.g., PBA] and caspase 3 
and 6 inhibitors [e.g., Z-DEVD-FMK and Z-VEID-FMK respectively] against noxious effects of 
hyperglycemia as demonstrated in our study. 
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 In this context, we explored the effects of glucotoxic conditions on the activation status of 
executioner caspases and the integrity of the nuclear lamina in cells exposed to chronic 
hyperglycemic conditions. Herein, we conducted experiments on insulin secreting INS-1 832/13 
cells, normal rodent and human islets by incubating with high glucose concentrations [20 mM for 
INS-1 832/13 and rat islets and 30 mM for human islets] for 24 hrs.  Findings from our 
experiments in INS-1 832/13 cells indicated that high glucose conditions lead to an increase in 
the cleaved form of both caspases 3 and caspase 6, indicating the activation of these 
executioner caspases, which resulted in a corresponding increase in the degraded product of 
lamin A as well as lamin B. Similarly, studies by Kivinen and associates have implicated the 
involvement of caspase 3 in the proteolysis of Nuclear Mitotic apparatus [NuMA] protein and the 
nuclear lamins in MCF-7:WS8 human breast cancer cell line [91]. Another in vitro study 
demonstrates that PC12 cells exposed to palmitic acid [PA/BSA 2:1 molar ratio] showed a 
significant increase in caspase activity measured fluorimetrically which could be co-related to an 
increase in PARP and lamin B cleavage as seen by Western blotting [92]. In the context of 
lamin A, Mintzer et al. have demonstrated that active caspase 6 has specificity for lamin A. The 
study shows that proteolytic cleavage of recombinant lamin A [GST-lamin A] increases with an 
increasing concentrations of human active caspase 6. They also state that a modest increase in 
GST-lamin A cleavage does occur at higher concentrations of caspase 3 [113]. In order to 
validate our preliminary findings in INS-1 832/13 cells, we conducted experiments under similar 
incubation conditions in primary rodent islets and islets obtained from human donors. 
Interestingly, we observed an increase in the activation of caspases 3 and 6 accompanied by 
the proteolytic cleavage of the nuclear lamins in the islet cells in a manner akin to our 
observations in INS-1 832/13 cells. In the above experiments, our findings indicated no 
significant effect of high glucose treatment on the expression of ZMPSTE24, the metallo-
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proteolytic enzyme involved in post translational processing of lamin A, in INS-1 832/13 cells 
and human islets. However, prenylation of these proteins, under conditions of glucolipotoxicity, 
needs to be studied in islet cells in a systematic manner.  
 Having examined the effects of glucotoxicity on caspases and lamins in INS-1 832/13 
cells and islets, we next tested our hypothesis in islets derived from animal models of type 2 
diabetes, namely the Zucker diabetic fatty rats. ZDF rats exhibit obesity along with diabetes and 
are widely used for research on type 2 diabetes [T2D]. These rats develop obesity and insulin 
resistance at a young age, and then with aging, progressively develop hyperglycemia. This 
hyperglycemia is associated with impaired pancreatic beta cell function and loss of pancreatic 
beta cell mass. Earlier reports from our own laboratory have shown an increase in the 
generation of NOX-2 induced reactive oxygen species [ROS] in the ZDF model [103]. This 
study also demonstrated an increase phosphorylation of JNK 1/2, a type of mitogen activated 
protein kinases [MAPK] which respond to stress stimuli and a significant decrease in the 
phosphorylated form of ERK1/2, another MAPK which plays a role in the cell survival pathway. 
Finding an increase in the activated caspases and cleaved lamins in islets obtained from the 
ZDF rat model and type 2 diabetic humans, further affirmed our hypothesis. 
 Our next aim was to elucidate the effect of chronic high glucose exposure on beta cell 
function. Insulin release is one of the direct measures of beta cell function and any impairment 
in either phase of insulin secretion, chiefly first phase, may be the earliest evidence of an 
individual’s progression towards type 2 diabetes. Numerous lines of evidence indicate that 
metabolic stress due to hyperglycemic conditions leads to a decline in glucose stimulated insulin 
secretion in the pancreatic beta cells. Hence, in the next set of studies, we assessed the insulin 
secretion capacity of INS-1 832/13 cells under high glucose exposure. The amount of insulin 
released into the culture medium under static incubation conditions was assessed by ELISA and 
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measured spectrophotometrically. Herein, we detected an increase in insulin secretion by the 
beta cells on short term glucose stimulus. However, cells that were chronically exposed to high 
glucose concentrations exhibited a significant impairment in insulin secretion, indicating that 
chronic hyperglycemia has a detrimental effect on beta cell function and contributes to the 
progression of type 2 diabetes. 
 Our findings also revealed considerable modifications in the subcellular distribution of 
lamin B in INS-1 832/13 cells under conditions of exposure to high glucose. What then might be 
the mechanisms underlying abnormal distribution of lamin B that we observed in beta cells 
exposed to high glucose conditions? To address this question, we made use of pharmacological 
inhibitors of the ER stress-mediated mitochondrial damage pathway in order to establish the 
causal role of ER stress in the release of cytochrome c into the cytoplasm, the subsequent 
activation of caspases and loss of integrity of the nuclear lamina. Thapsigargin, a known inducer 
of ER stress in many cell types inhibits the sarcoplasmic/ ER calcium ATPase [SERCA] pump, 
which regulates the influx of calcium ions from the cytoplasm of the cell into the ER lumen. 
Induction of ER stress by thapsigargin as evidenced by the upregulation of CHOP expression 
also induced activation of caspases in the islet beta cell, along with an increase in lamin B 
degradation. Extant studies and data obtained in our study suggest that increased oxidative and 
ER stress leading to mitochondrial dysfunction could be a result of hyperglycemic conditions. As 
a consequence, executioner caspases in the cytoplasm are activated by cytochrome C released 
from the dysregulated mitochondria. Moreover, the significant inhibition by PBA of CHOP 
expression, caspase 3 activation and lamin B degradation, that were augmented under high 
glucose exposure, further strengthens the notion of the involvement of an ER mediated pathway 
in the beta cell under glucotoxic conditions. Lastly, our observations also support reports by 
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Tang et al. establishing clear roles for the oxidative stress-ER stress signaling axis in glucose-
induced beta cell dysfunction in vivo in rats [114] 
 Investigation of the association of intracellular calcium levels in this pathway, led to the 
suggestion that accumulation of cytosolic calcium plays a contributory role in regulation of 
glucose-induced effects on caspase 3 activation and lamin B degradation. Studies conducted by 
Wang et al. demonstrate the participation of intracellular calcium in ER stress pathway in the 
pancreatic beta cell. To this end they have uncovered the cytoprotective effects of nifedipine, a 
dihydropyridine calcium channel blocker via a decrease in the phosphorylation of eukaryotic 
initiation factor 2α [eIF2α], expression of CHOP and active caspase 3 [94]. Another 
phenylalkylamine calcium channel blocker, verapamil, has been utilized by Xu and colleagues, 
wherein they demonstrated the inhibitory effect of verapamil on increased expression of 
thioredoxin-interacting protein [TXNIP], which is upregulated in diabetic conditions and 
reestablished insulin secretion in vivo in 8 week old, leptin-deficient, type 2 diabetic BTBRob/ob 
mice. This background and our current findings further reinforce the idea that accumulation of 
calcium in the cytoplasm due to increased influx via the L-type calcium channels located on the 
cell membrane would eventually lead to mitochondrial damage due to calcium overload and 
further cause disruption of cellular function. Inhibitors of long lasting calcium channels [e.g., 
verapamil and nifedipine] seem to support the beta cells in defense against stress stimuli and 
enhance beta cell survival and function [93, 94, and 115]. Moreover, a recent study by Zhou et 
al. has demonstrated the protective effects of nifedipine-mediated inhibition of calcium channels 
in pancreatic beta [MIN6] cells and mouse islets treated with palmitic acid. Further they have 
also suggested the involvement of ER stress in lipotoxicity, evidenced by an increase in 
phosphorylation of eukaryotic initiation factor 2α [eIF2α] and expression of CHOP which were 
reversed by nifedipine [116]. Along these lines we put forward a working model that implicates 
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excessive influx and build up of cytosolic calcium as one of the causal factors leading to 
hyperglycemia-induced activation of caspase 3 and 6 and proteolytic degradation of lamins A 
and B. 
 The preferential detection of certain amino acid chain arrangements on the substrate 
proteins by individual caspases has been utilized in building up specific peptide inhibitors of 
these proteases. These peptide inhibitors of caspases readily permeate the cell membrane and 
bind to the catalytic sites on the caspases based on preferential sequence specificity and in 
doing so, impede the events downstream of caspase activation. In vitro studies by Huo et al. in 
the HIT-T15 beta cell line have shown that Z-VDVAD-FMK, a specific inhibitor of caspase 2 has 
a protective effect on the cells against detrimental effects of mycophenolic acid [MPA], thereby 
aiding their survival [95]. Furthermore, another study which utilized human Fas cDNA for 
transfection into murine βTC-1 cell lines demonstrated the involvement of caspase 3 in Fas- 
mediated death signaling pathway. In addition, on using Z-Asp-Glu-Val-Asp fluoromethyl ketone 
[Z-DEVD-FMK] a specific inhibitor of caspase 3, protected against Fas-induced cell death [96]. 
In a similar mouse model transfected with human Fas, a caspase 6 inhibitor was observed to 
exert protective effects against palmitic acid-induced effects on the cells [97]. Our own data 
obtained from studies using Z-DEVD-FMK and Z-VEID-FMK specific inhibitors of caspase 3 and 
caspase 6 activation respectively, in INS-1 832/13 cells points out the involvement of both these 
executioner caspases in the disassembly of the nuclear lamina via proteolytic cleavage and the 
reversal of these effects by the peptide inhibitors [117]. We recognize potential caveats in our 
studies involving the use of inhibitors of caspase 3 and caspase 6. While we were able to 
demonstrate their inhibitory effects on caspase activity and lamin degradation under high 
glucose conditions, thus confirming our hypothesis, we also observed that they exerted 
untoward effects on beta cells under low glucose conditions. Additional studies to test the 
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possibility that the addition of the chemical or peptide inhibitors to cells under basal conditions 
may trigger such a response would help in gaining further understanding of this observed 
phenomenon.  
Further to elucidate the role of post translational prenylation of nuclear lamins towards 
cell stability and function in our studies we utilized pharmacological inhibitors of prenylation such 
as, statins [simvastatin], FTIs and GGTIs. Statins belong to the cholesterol lowering class of 
drugs and are one of the most widely used drugs in the treatment of cardiovascular diseases. 
The first ever statins isolated from the Penicillium species were compactin and mevastatin in the 
year 1976, followed by lovastatin in 1980. Subsequent studies revealed their property of 
inhibition of the HMG-CoA reductase enzyme and the associated blocking of cholesterol 
biosynthesis. However the most important benchmark in the discovery of statin molecules was 
in the year 1987; when Simvastatin, a semi-synthetic compound derived using the lovastatin 
parent structure was approved for use in humans.  In the following years several purely 
synthetic statin moieties were derived, namely; fluvastatin, atorvastatin, cerivastatin, with 
rosuvastatin and pitavastatin being the most recently developed in 2003 and 2009 respectively 
[118-121]. In 2001, cerivastatin was withdrawn from the market due to renal malfunction 
associated deaths that were reported in the post marketing surveys [122]. The basic 
mechanism of action is by inhibition of HMG-coA reductase in the cholesterol biosynthesis 
pathway [123]. The inhibition of the reductase enzyme blocks the production of mevalonic acid 
MVA which is a precursor to cholesterol. The primary effects of statins are inhibition of 
cholesterol synthesis and increasing LDL uptake [124, 125]. However, based on recent 
evidence from a number of studies, trials and meta analysis, the U.S. Food and Drug 
Administration [FDA] has approved important safety label changes for statins that indicate the 
association of statins with an increase in hemoglobin A1C and fasting glucose levels. Despite 
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these reports, the underlying molecular mechanisms of these effects of statins need to be 
further explored in the context of pancreatic beta cells and type 2 Diabetes. In addition to 
blocking cholesterol synthesis, statins also prevent the formation of intermediate metabolites of 
this pathway, namely: farnesyl pyrophosphate [FPP] and geranylgeranyl pyrophosphate [GGPP] 
that are involved in post translational prenylation of several proteins [Rho, Rab, Ras, lamins], 
thereby preventing post translational prenylation of these proteins. In this context, a variety of 
pharmacological inhibitors that interfere with the activities of the enzymes farnesyl transferase 
[FTase] and geranylgeranyltransferase [GGTase] have been developed. Figure 6-2 depicts the 
structures of a few inhibitors of prenylation, namely; simvastatin, farnesyl transferase inhibitor 
[FTI-277] and geranylgeranyltransferase inhibitor [GGTI-2147]. 
Figure 6-2: Chemical structures of inhibitors of protein prenylation 
 A recent study carried out by Ishikawa and associates reported that different statin 
molecules have differential effects on the insulin release by the beta cell. In this study they 
SIMVASTATIN
FTI‐277 GGTI‐2147
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utilized MIN6 cells to study beta cell function by measuring glucose stimulated insulin secretion 
in the cells post treatment with various statin drugs and demonstrated that decreasing 
hydrophobicity of the molecules enhances their capacity to impair insulin secretion in the cells. 
Therefore, the more lipophilic statins such as lovastain and simvastatin demonstrated a more 
pronounced effect [126]. Based on their studies with lovastatin in MIN6 beta cells, Tsuchiya et 
al. propose that statin-mediated inhibition of cholesterol biosynthesis pathway and thereby 
depletion of the intermediate metabolites such as mevalonate, squalene and geranylgeranyl 
pyrophosphate is a contributory factor towards the reduction in insulin content of the cell, as well 
as its capacity to efficiently secrete insulin [127]. Early studies by Metz et al. demonstrated that 
inhibition of PTM of GTP binding proteins brought about a decrease in the insulin secretion in 
intact rat islets. In this study, they also showed that lovastatin treatment of the islets caused a 
hindrance in their association with the membrane and markedly diminished glucose stimulated 
insulin secretion, which could be precluded by supplementing the culture media with mevalonic 
acid [128]. Several lines of evidence in other cell types implicates that inhibition of requisite 
post-translational modifications of lamins [A and B], including farnesylation and 
geranylgeranylation results in alterations in cell metabolism and can have detrimental effects on 
the cell. For example, using TAD-2 thyroid cell line Matola and associates reported that 
lovastatin, an inhibitor of protein farnesylation and geranylgeranylation, induces cell death by 
inducing mitochondrial dysfunction, cytochrome C release, caspase 3 activation and lamin B 
degradation [129]. Likewise, more recent studies by Chang et al. have demonstrated 
abnormalities in lamin A processing following inhibition of its farnesylation using FTIs and also 
GGTIs. They reported significant accumulation of unprocessed lamin A intracellularly [130].  
 In order to study the regulatory role of farnesylation in lamins, several studies utilizing 
farnesyltransferase inhibitors have been conducted. In one such study Adam et al.  reported an 
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increase in unprocessed lamin B2 and lamin A and a decrease in mature lamin B1 in human 
fibroblasts treated with FTIs [131]. Hutchinson-Gilford Progeria Syndrome [HGPS] is a rare 
premature aging disorder caused by point mutation G608G [GGC>GGT] within exon 11 of 
LMNA gene encoding A-type nuclear lamins. This mutation results in the expression of a 
truncated protein, progerin, deficient in 50 amino acids in the carboxyl-terminus of prelamin A, 
which still retains a farnesylated cysteine at its carboxyl terminus, a modification involved in 
HGPS pathogenesis. Previous studies in cellular and animal models of HGPS have 
demonstrated that FTI treatment improves abnormal nuclear morphology and phenotype [132]. 
Mallampalli et al. also demonstrated that FTI [rac-R115777] significantly improved abnormal 
nuclear morphology in HeLa cells [133] and also FTI-276 improved nuclear shape abnormalities 
in keratinocytes of transgenic mice expressing progerin in epidermis or a combination therapy of 
pravastatin and zoledronate by immunofluorescence microscopy [134]. In HGPS mouse model 
dose-dependent administration of the FTI tipifarnib [R115777, Zarnestra] significantly prevented 
loss of vascular smooth muscle cells in the large arteries and also delayed progression of 
cardiovascular disease [135]. In another study along these lines, R115777 a potent, orally 
active FTI, was recently investigated in a phase I dose-ranging study in patients with acute 
leukemias. R115777 dose dependently inhibited farnesylation of lamin A and HDJ-2 [136] 
suggesting further evaluation of this compound in clinical studies. In a recent clinical trial study 
in children prone to HGPS, 25 patients were subjected to a 2 year treatment with lonafarnib 
[FTI]. All subjects improved in one or more of the following: gaining additional weight, better 
hearing, improved bone structure and/or, most importantly increased flexibility of blood vessels. 
This study presented preliminary evidence that lonafarnib may improve the detrimental 
phenotypical changes associated with this disorder [137].  
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 Interestingly, significant effects on mitochondrial and nuclear stability indicated by 
increased activation of caspase 3 and degradation of lamin B were observed in our studies with 
simvastatin, which demonstrate the consequences of inhibition of post-translational prenylation 
in INS-1 832/13 cells as well as rat islets. In addition, we observed clear alterations in cell 
morphology [rounding], and a marked decrease in cell survival and GSIS. Moreover, a 
significant increase in the activation of p38 MAP Kinase, which has been implicated in 
hyperglycemia associated beta cell dysfunction, was observed along with a marked decrease in 
the phosphorylation of ERK 1/2 which plays a crucial role in cell survival and function. The 
effects of this lipophilic statin on caspase 3 and lamin B were mimicked by a specific inhibitor of 
farnesyl transferase, FTI-277. However GGTI-2147, which specifically inhibits 
geranylgeranyltransferase-I, could not produce the same effects as seen in INS-1 cells and rat 
islets. These observations point out the possibility that the caspase 3 activation and lamin B 
degradation effects are farnesylation dependent. However, whether this is a result of depletion 
of the substrate farnesyl pyrophosphate [FPP] or if it is due the inhibition of the enzyme FTase 
or a combination of the two needs to be further investigated. In this context, recent reports from 
our laboratory in insulin secreting cells have shown that the degradation of the regulatory 
subunit of FTase was caspase 3 mediated [93]. Also, evidence in other cell types indicated a 
caspase 3 dependent mechanism involved in the degradation of the common α subunit of 
FTase and GGTase [138].  
 In an attempt to identify the patho-mechanism of inhibition of prenylation using statins or 
farnesylation inhibitors Pelaia et al. have demonstrated in 2 lung cancer cell lines, namely 
CALU-1 [squamous cell line] and GLC-82 [adenocarcinoma cell line] that inhibition of 
prenylation with these agents caused a decrease in the phosphorylation of ERK 1/2 and showed 
detrimental effects on cell morphology, thereby implicating the Ras/Raf/MEK/ERK pathway 
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[139]. This observation was confirmed in glioma cell lines by Afshordel and associates wherein 
they inhibited prenylation with lovastatin and perillyl alcohol [140]. Bonifacio and colleagues 
have identified the AKT/mTOR pathway as a target for statin mediated detrimental effects in 
myotubes. 24 hr incubations of C2C12 myotubes with 10 – 50 µM concentrations of simvastatin 
and atorvastatin caused a decrease in AKT phosphorylation thereby inhibiting its activation. In 
addition they observed a parallel increase in the activation of caspases and the downstream 
cleavage of PARP. Comparable effects observed in mice skeletal muscles indicate that probing 
further into statin-mediated effects on the AKT/mTOR pathway would provide important leads in 
the identification of prospective therapeutic targets [141]. Collectively, these observations point 
out the significance of post translational modifications, specifically farnesylation in maintaining 
the function and integrity of the nuclear lamins. 
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CHAPTER 7 
CONCLUSION AND FUTURE DIRECTIONS 
 
 The overall goal of my Ph.D. project is to understand the cellular mechanisms involved 
in the pathology of islet beta cell dysfunction under conditions of chronic exposure to high 
glucose [glucotoxicity]. Salient features of my research work are:  
 Exposure of insulin-secreting pure beta cells [INS-1 832/13 cells], normal rodent islets 
and human islets to glucotoxic conditions results in the activation of executioner 
caspases 3 and 6, and subsequent degradation of their downstream target proteins, 
such as nuclear lamins A and B.  I also observed a significant inhibition of glucose-
stimulated insulin secretion under these conditions. 
 Glucotoxic conditions promoted significant alterations in the subcellular distribution of 
nuclear lamins [e.g., increased abundance in cytosol] suggesting the collapse of nuclear 
compartment under these conditions. 
 Specific inhibitors of caspase 3 and caspase 6 attenuated high glucose-induced caspase 
activation and lamin degradation. 
 Similar increases in the activation of executioner caspases and degradation of nuclear 
lamins A and B were seen in islets derived from the ZDF rat, a model for T2DM and 
islets from T2DM human donors. 
 In a manner akin to thapsigargin, a known inducer of ER stress, glucotoxic conditions 
also significantly increased ER stress as evidenced by increased expression of CHOP, a 
marker for ER stress. Moreover, exposure of beta cells to thapsigargin resulted in the 
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activation of executioner caspases and lamin degradation, thus suggesting that caspase 
activation and lamin degradation seen under the duress of high glucose may, in part, be 
due to increased ER stress. This is further confirmed by my observations that PBA, a 
known inhibitor of ER stress, markedly attenuated CHOP expression, caspase activation 
and lamin degradation in beta cells exposed to glucotoxic conditions.  
 Nifedipine, a known inhibitor of membrane-associated L-type calcium channels, also 
inhibited high glucose-induced caspase activation and lamin degradation; these findings 
suggest that increased levels of intracellular calcium in beta cells exposed to glucotoxic 
conditions could contribute to the mitochondrial [caspase activation] and nuclear [lamin 
degradation] defects.  
 Inhibition of protein [lamin] prenylation with simvastatin, a known inhibitor of 
farnesylation and geranylgeranylation, promoted mitochondrial and nuclear defects as 
evidenced by caspase activation and lamin degradation in INS-1 832/13 cells and 
normal rodent islets. More site-specific inhibitors of protein farnesylation [FTI-277] also 
caused caspase activation and lamin degradation suggesting potential involvement of a 
farnesylated protein in the induction of mitochondrial defects. It is also likely that 
inhibition of farnesylation of lamins by FTI-277 and simvastatin make lamins more 
vulnerable for degradation and nuclear collapse. My findings also suggested that 
inhibition of protein prenylation leads to increase in stress kinase [p38 kinase] and 
inhibition of ERK1/2, known for its cell survival roles. Collectively, these alterations in cell 
signaling pathways could promote intracellular stress and demise. 
 
 Based on the above findings, I conclude that chronic exposure of beta cells to 
hyperglycemic conditions leads to increased intracellular calcium levels [calcium overload] and 
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ER stress leading to loss in mitochondrial dysregulation, including loss in mitochondrial 
permeability pore transition, leakage of cytochrome C into cytosol and activation of executioner 
caspases. These events, in turn, lead to degradation of key cellular proteins, such as nuclear 
lamins, resulting in the collapse of nuclear compartment and accumulation of lamin degradation 
products in cytosolic compartment. Collectively, alterations in these cellular events lead to a loss 
in functional beta cell mass and onset of diabetes. I believe that my studies not only provided 
mechanistic insights into mitochondrial and nuclear dysfunction in beta cells under the duress of 
glucotoxic conditions, but they also provided fresh insights into potential beneficial 
[cytoprotective] effects of calcium channel blockers in the treatment of T2DM in humans. 
Future directions: 
 While my research work provided novel insights into islet dysfunction in diabetes, I 
believe that there are several knowledge gaps that need to be filled. Some of those are listed 
below. 
 
 First, we need to quantify the intracellular calcium levels in the beta cell following 
exposure to glucotoxic conditions. Data from calcium channel blockers are encouraging, but it is 
important to quantify the levels of calcium in cells treated without or with glucose and calcium 
channel blockers and correlate those with cellular indices of apoptosis. Further, we need to 
verify these in vitro findings in animal models of T2DM to see if administration of calcium 
channel blockers prevents/halts islet dysfunction and diabetes in these model systems. 
 
 Second, we need to investigate metabolic alterations in beta cells exposed to saturated 
fatty acids, such as palmitate [lipotoxic conditions] and, ideally, glucolipotoxic conditions. These 
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studies would provide additional insights into combined effects of glucose and lipids in inducing 
mitochondrial and nuclear defects. 
 
 Third, additional studies are needed to further asses the roles of post-translational 
farnesylation of lamins in maintaining the integrity of the nuclear envelop. This can be 
addressed first by in vitro approaches involving use of inhibitors of protein prenylation and 
siRNA-mediated knockdown of prenyltransferases. My studies have identified the lamin 
processing enzyme in the islet, and therefore, it is likely that lamins might undergo additional 
PTMs [carboxylmethylation] that might be requisite for maintaining the integrity of nuclear 
envelop. Very little is known with regard to alterations in these modification signaling events in 
the diabetic islet. 
 
 Lastly, LMNA mutations have been shown in human subjects with severe metabolic 
syndrome. More needs to be understood with regard to potential alterations in post-translational 
prenylation and phosphorylation of lamins as cause for pathology of metabolic disorders 
including obesity and T2DM.  
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Type 2 Diabetes [T2DM] is a chronic condition resulting from gradual failure of 
pancreatic beta cells to synthesize and secrete sufficient insulin to meet the metabolic demands 
and the inability of tissues [muscle, adipose and liver] to efficiently utilize the secreted insulin 
leading to an overall increase in blood glucose levels [hyperglycemia]. As indicated by recent 
estimates from the International Diabetes Federation, the prevalence of the disease in the year 
2014 has risen to a record 387 million worldwide. The main objective of my project was to study 
the mechanisms involved in pancreatic beta cell dysfunction in diabetes, specifically in 
elucidating the role of endoplasmic reticulum [ER] - mitochondria axis, executioner caspases 
and their target substrates; specifically nuclear lamins.  
Results obtained from our studies in pure beta cells [INS-1 832/13], primary rodent and 
human islets strongly suggest that glucotoxicity induced pancreatic beta cell damage involves 
the degradation of nuclear lamins A and B, via ER stress-mediated activation of executioner 
caspases 3 and 6. We confirmed this by employing pharmacological approaches [inhibitors of -
ER stress, -caspase activation and calcium channel activation] to gain mechanistic insights into 
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beta cell dysfunction under the duress of chronic hyperglycemia. Further, we were able to 
corroborate these findings in the ZDF rat, an animal model for T2DM and in islets obtained from 
human donors with T2DM. Also, our findings revealed significant attenuation of glucose-
stimulated insulin secretion [GSIS] in beta cells exposed to glucotoxic conditions suggesting 
cellular dysfunction under these conditions. Post-translational prenylation of lamins is important 
for their localization into the nuclear membrane, and subsequent interaction with other proteins. 
Our results indicate that inhibition of prenylation by simvastatin and a site-specific inhibitor of 
protein farnesylation [FTI-277], promoted mitochondrial and nuclear defects as evidenced by 
caspase activation and lamin degradation in INS-1 832/13 cells and normal rodent islets. Our 
findings also suggest that inhibition of protein prenylation leads to increase in stress kinase [p38 
kinase] and inhibition of ERK1/2, known for its cell survival roles. Collectively, these alterations 
in cell signaling pathways could promote intracellular stress and demise. 
 We hope that data accrued in these studies will provide fresh insights into the 
identification of the intracellular mechanisms involved in beta cell malfunction in nutrient 
overload and metabolic stress. These studies will also aid in the identification of potential drug 
targets for the management and/or prevention of diabetes. 
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